

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Table of Contents

Click on project titles to see full abstracts

PI First Name	PI Last Name	Title	Host Campus/Institution	Start Date
Emma	Farley	<a href="#">Predicting causal variants in melanoma</a>	San Diego	10/1/2024
Shiri	Gur-Cohen	<a href="#">Identifying distinct lymphovascular drivers of tumor initiation and evolution</a>	San Diego	10/1/2024
Vanessa	Jonsson	<a href="#">AI based discovery of novel T cell therapies for diverse immunogenetic backgrounds</a>	Santa Cruz	10/1/2024
Noriko	Satake	<a href="#">Targeting RNA splicing in B-cell acute lymphoblastic leukemia</a>	Davis	10/1/2024
Peter	Zage	<a href="#">Targeting Oncogene-Induced Replication Stress for Neuroblastoma</a>	San Diego	10/1/2024
Jack	Bui	<a href="#">Self-amplifying mRNA to co-opt anti-viral responses for tumor immune therapy</a>	San Diego	10/1/2023
Naseem	Esteghamat	<a href="#">Identifying Disparities in Autologous HCT Utilization for DLBCL in California</a>	Davis	10/1/2023
Kent	Leach	<a href="#">Influence of growth hormones and mechanical loading on osteosarcoma progression</a>	Davis	10/1/2023
Karen	Lindsay	<a href="#">Exploring pathways for fetal programming of offspring cancer risk through prenatal diet</a>	Irvine	10/1/2023
Yunxia	Lu	<a href="#">A feasibility study of remote diet-related small habits intervention in cancer survivors</a>	Irvine	10/1/2023
Dionicio	Siegel	<a href="#">Small Molecule Inhibition of GNAS; Creating the First Targeted Treatments for Appendix Cancer</a>	San Diego	10/1/2023
Jeffrey	Esko	<a href="#">Heparan Sulfate Biomarker for Pancreatic Cancer</a>	San Diego	10/1/2022
Matthew	Hangauer	<a href="#">Decoding Cancer Acquired Drug Resistance</a>	San Diego	10/1/2022
Gerardo	Mackenzie	<a href="#">Evaluation of ketogenic diet strategies for pancreatic cancer-associated cachexia</a>	Davis	10/1/2022
Kara	McCloskey	<a href="#">Integrated Model of Cancer, Vasculature, and Immune System</a>	Merced	10/1/2022
Jun	Sheng	<a href="#">Flexible Robotic Evacuator for Minimally Invasive Brain Tumor Therapy</a>	Riverside	10/1/2022
Hao-Chuan	Wang	<a href="#">Enhancing Online Group Fitness Exercise for Health Improvement for Patients with Cancers</a>	Davis	10/1/2022
Tayloria	Adams	<a href="#">Electrical Impedance Spectroscopy for Monitoring the Chemoresistance of Prostate Cancer Cells</a>	Irvine	10/1/2021
Michael	Campbell	<a href="#">Evaluating cost effective care for differentiated thyroid cancer</a>	Davis	10/1/2021
Nicholas	Pannunzio	<a href="#">Etiology of Ph-like ALL and the mechanisms driving Latinx cancer disparities</a>	Irvine	10/1/2021
Feng	Qiao	<a href="#">Cancer therapeutics via small molecule-mediated p53 mutant reactivation</a>	Irvine	10/1/2021
Candice	Sauder	<a href="#">Outcomes for premenopausal women with triple negative secondary breast cancer</a>	Davis	10/1/2021

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

PI First Name	PI Last Name	Title	Host Campus/Institution	Start Date
Weiwei	Zhang	<a href="#">Neurocognitive Processes for Mammographic Detection of Breast Cancer</a>	Riverside	10/1/2021
Dorothy	Apollonio	<a href="#">Effects of tobacco and cannabis policy implementation on consumption</a>	San Francisco	10/1/2020
Jeremy	Chien	<a href="#">Advancing VCP inhibitors as experimental therapeutics in ovarian cancer</a>	Davis	10/1/2020
Michael	Hoyt	<a href="#">Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Latinos with Testicular Cancer</a>	Irvine	10/1/2020
Chang-il	Hwang	<a href="#">Epigenetic landscape of DNA methylation in pancreatic cancer progression</a>	Davis	10/1/2020
Loren	Mell	<a href="#">"Lymphomizing" Treatment of Head and Neck Cancer using Involved Field RT with Chemo-Immunotherapy</a>	San Diego	10/1/2020
Tyler	Seibert	<a href="#">A polygenic score for prediction of aggressive and fatal prostate cancer in multi-ethnic populations</a>	San Diego	10/1/2020
Zuzanna	Siwy	<a href="#">Label free, high throughout detection and separation of individual breast cancer stem cells</a>	Irvine	10/1/2020
Elysia	Alvarez	<a href="#">Patterns of Care and Outcomes in AYAs with Germ Cell Tumors</a>	Davis	1/1/2020
Lee	Bardwell	<a href="#">Novel Links Between Wnt Signaling, Centrosomes, and Cancer</a>	Irvine	1/1/2020
J. Sebastian	Gomez Diaz	<a href="#">Detecting tumor-specific exosomes on a chip</a>	Davis	1/1/2020
Selma	Masri	<a href="#">Linking the Circadian Clock and Cancer</a>	Irvine	1/1/2020
Sha	Sun	<a href="#">Downregulation of XIST in Ovarian Cancer and Its Mechanisms</a>	Irvine	1/1/2020
Sora	Tanjasiri	<a href="#">Samoan Healthy Eating and Active Living (HEAL)</a>	Irvine	1/1/2020
Carolina	Arias	<a href="#">Unveiling targets for treating malignancies of viral origin</a>	Santa Barbara	1/1/2019
Siddharth	Dey	<a href="#">Studying tumor heterogeneity using single-cell epigenomics</a>	Santa Barbara	1/1/2019
Douglas	Kellogg	<a href="#">Control of cell growth in normal and transformed cells</a>	Santa Cruz	1/1/2019
Pradip	Mascharak	<a href="#">Improving outcome of cancer chemotherapy with CO</a>	Santa Cruz	1/1/2019
Laura	Romo	<a href="#">Think Biology: Healthy Teen Lifestyles and Cancer Prevention</a>	Santa Barbara	1/1/2019
Jin	Zhang	<a href="#">Photothermal Therapy of Oral Squamous Cell Carcinoma</a>	Santa Cruz	1/1/2019
Scott	Atwood	<a href="#">Recurrent GLI mutations in drug-resistant skin cancer</a>	Irvine	1/1/2018
Robert	Canter	<a href="#">Outcomes in Stage IV Cancer Patients with Bowel Obstruction</a>	Davis	1/1/2018
Frederic	Chedin	<a href="#">R-loop Driven Oncogenic Translocations in Prostate Cancer</a>	Davis	1/1/2018

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

PI First Name	PI Last Name	Title	Host Campus/Institution	Start Date
Celia	Goulding	<a href="#">Repurposing a toxin-immunity pair to selectively kill cancer</a>	Irvine	1/1/2018
Michael	Kent	<a href="#">The Role of p21 Phosphorylation at S123 in Tumor Suppression</a>	Davis	1/1/2018
Kai	Kessenbrock	<a href="#">Studying breast cancer initiation in single cell resolution</a>	Irvine	1/1/2018
Noriko	Satake	<a href="#">Leukemia Stem Cells in B-Cell Acute Lymphoblastic Leukemia</a>	Davis	1/1/2018
Szu-Wen	Wang	<a href="#">Novel cancer metabolite-triggered drug delivery</a>	Irvine	1/1/2018
*Stella	Tommasi	<a href="#">Investigating the carcinogenicity of e-cig</a>	USC	7/1/2016
*Celia	Kaplan	<a href="#">Lung Cancer Screening: The Views of Patients and Physicians</a>	San Francisco	7/1/2015
*Dian	Yang	<a href="#">Genomic approaches to identify SCLC biomarkers</a>	Stanford	7/1/2015
*Xiaohe	Liu	<a href="#">CTCs for early detection and characterization of lung cancer</a>	SRI	12/1/2014
*Michael	McNitt-Gray	<a href="#">Ultra Low Dose, Effective CT for Lung Cancer Screening</a>	Los Angeles	8/1/2013
*Lori	Sakoda	<a href="#">Shared Genetics of COPD and Lung Cancer</a>	Kaiser	8/1/2013
*Rod	Lew	<a href="#">Alliance for Data Dissemination to Achieve Equity (ADEPT)</a>	APPEAL	5/1/2011

\*Awards funded through [Tobacco-Related Disease Research Program](#)

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Predicting causal variants in melanoma

*Campus:* UCSD

*Principal Investigator:* Emma Farley

*Start Date:* 10/01/2024

*End Date:* 09/30/2025

*Amount:* \$95,000

*Abstract:*

All aspects of cancer are driven by changes in gene expression. Enhancers are genomic elements that control the timing, location, and levels of expression of a particular gene or genes, as such, enhancers provide the instructions for gene expression. While there has been extensive focus on protein-coding variants and genomic changes that alter protein-coding regions, how enhancer variants contribute to cancer initiation, progression, metastasis, and response to therapy is poorly studied. Enhancers harbor the majority of variants associated with diseases including cancers, but pinpointing causal variants is a major challenge because they are typically embedded within a sea of inert variants. This gap in our knowledge is stalling efforts to harness the full potential of genomic data to understand and treat cancer. A clear understanding of which enhancer variants contribute to various aspects of cancer is vital to understand the genetic basis of cancer initiation, progression, to develop novel therapeutics, improve diagnosis, and stratify patients for more targeted treatments. In this study, we will pilot a novel approach to identify enhancer variants that contribute to changes in gene expression in melanoma. We are experts in identifying causal variants within enhancers that alter gene expression and cellular identity within the context of the developing embryo. We have found that low-affinity binding sites are critical for precise control of gene expression. The prevalent use of low affinity sites within enhancers creates a vulnerability within genomes whereby SNVs can increase the affinity of binding sites within enhancers causing gain of function gene expression that alters cellular identity. We have demonstrated this in the context of heart and limb development. We now wish to apply this knowledge to gain insight into causal variants that contribute to various aspects of cancer. We plan to initially focus on metastasis, immunotherapy response and drug resistance in melanoma. In our preliminary study we have shown that an affinity optimizing SNVs found in a somatic melanoma eQTL increases expression of DAAM1 and increased cell migration. Successful completion of this project will uncover the contribution of enhancer variants to cancer progression and treatment.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Identifying distinct lymphovascular drivers of tumor initiation and evolution

Campus: UCSD

Principal Investigator: Shiri Gur-Cohen

Start Date: 10/01/2024

End Date: 09/30/2025

Amount: \$85,000

#### Abstract:

All forms of cancer begin with genetic alterations in otherwise healthy cells. Yet, these alone are insufficient to predict an individual's disease onset and risks, indicating that nongenetic events within the tumor ecosystem ('niches') play a role in unleashing tumorigenesis. Stem cells are the origin of many life-threatening malignancies and are notorious for their tight dependency on the surrounding microenvironment. Despite undisputed importance, our understanding of how the ecosystems that stem cells inhabit direct oncogenic fate flexibility is limited. Equally, it remains a mystery whether early-stage tumor initiation through advanced disease progression is supported by overlapping or distinct niches. These gaps in knowledge can largely be attributed to a dearth of tools and models that capture the oncogenic stem cell identity landscape in intact tissues.

The lymphatic vascular network is an emerging, previously unrecognized niche entity for epithelial stem cells, yet much of the mystery of the lymphatic niches in directing tumorigenesis remains untapped. The goal of our proposed work is to determine how distinct vascular cues drive oncogenic flexibility and tumorigenesis in rare pre-cancer stem cells. Using deep imaging and sequencing approaches in skin squamous cell carcinoma, we discovered that lymphatic vascular insufficiency predisposes to malignant transformation. Detailed temporal volumetric imaging revealed that oncogenic plasticity propelling the transition from benign to metastatic carcinoma is preceded by dynamic lymphatic remodeling. These results raise the intriguing possibility that lymphatic niches evolve during disease progression, directing oncogenic tolerance in tumor-initiating cells while becoming a significant barrier to cancer treatments. To fill these knowledge gaps, we aim to determine how vascular circuits shape oncogenic tolerance in mutated yet untransformed cells in concert with their evolving niches, and to identify non-mutational drivers that build the pro-metastatic niche using our newly developed enhancer-based proximity sensor technology. Our innovative approach will define how vascular circuits shape the stem cell oncogenic landscape. A successful outcome of these studies holds promise for the development of therapeutics that block early cancer progression and pave the way to combat advanced metastatic disease.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### AI based discovery of novel T cell therapies for diverse immunogenetic backgrounds

Campus: UCSC

Principal Investigator: Vanessa Jonsson

Start Date: 10/01/2024

End Date: 09/30/2025

Amount: \$94,961

#### Abstract:

The pursuit of novel T cell targets that unleash potent anti-cancer immune responses is hindered by the lack of scalability of traditional wet lab techniques — imposing burdensome costs and inefficiencies on immunotherapy target discovery. While T cell therapies have brought about a transformative impact on cancer treatment, their effectiveness is limited to a few cancer types, and has struggled to be applicable to individuals with diverse immunogenetic profiles. There is an urgent need to shift our focus towards automated target discovery, with the aim of reaching a broader patient population.

The overall goal of this project is to propel the discovery of targets for novel T-cell therapies and expand their use in patients with diverse immunogenetic backgrounds by deploying AI-driven tools to analyze high throughput RNA sequencing data. My lab has recently developed an AI-driven framework and two pivotal datasets, containing 2 million publicly available single T cell transcriptomes, with matching T cell receptor data, and experimentally validated T cell antigen specificity data, extracted from 265 cancer patients, across 30 cancer types. This framework aims to accelerate the discovery of novel T cell therapies for cancer, promising faster and more cost effective development, with broader accessibility to diverse patient populations. Notably, ours is the only known methodology capable of automating the design of T cell therapies using data from an individual's adaptive immune system, without knowledge of their cancer genome.

We harnessed our AI-driven framework and database to discover a novel T cell therapy that can target two key cancer antigens: insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2), prevalent in multiple cancer types, and associated with poorer patient survival, and well known target, melanoma antigen recognized by T-cells 1, (MART1). In collaboration with Dr. Powell at the UPenn, we are testing this newly discovered immunotherapy for clinical translation. We propose to leverage our framework for the discovery of: 1) multispecific T cell therapies simultaneously targeting multiple cancer antigen(s) and 2) T cell therapies applicable to populations with diverse immunogenetic backgrounds. The CRCC funding will allow us to discover and gather preliminary data on additional targets that will be leveraged to obtain NIH funding.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Targeting RNA splicing in B-cell acute lymphoblastic leukemia

Campus: UCD

Principal Investigator: Noriko Satake

Start Date: 10/01/2024

End Date: 09/30/2025

Amount: \$85,000

#### Abstract:

The proposed project is built upon our prior transcriptomic studies that led us to a new area of research studying the role of RNA splicing in cancer. SF3B1 is a core component of the spliceosome and an essential protein in the RNA splicing process. Mutations in SF3B1 are a common cause of RNA dysregulation in multiple carcinomas and myeloid malignancies, and targeting the spliceosome has been evaluated in preclinical models and clinical trials. On the other hand, aberrant expressions, not mutations, of SF3B1 are common in cancers, including sarcomas and lymphoid malignancies, suggesting the role of RNA splicing can be different in different cancers.

Recently a study on aberrant RNA splicing and its potential as a therapeutic target in T-cell acute lymphoblastic leukemia was published. Aberrant RNA splicing has also been reported in B-cell acute lymphoblastic leukemia (B-ALL); however, its role and therapeutic potential are not yet known. Our preliminary studies in B-ALL suggest that leukemia-initiating cells (LICs) that we discovered use unique RNA splicing as a survival mechanism and are sensitive to SF3B1 targeting.

Therefore, targeting leukemia cells, including LICs, has the potential to eradicate leukemia at its root. LICs are believed to be the reason for disease relapse, and relapsed diseases still have very poor outcomes. Our project has the potential to overcome the significant challenges of treating relapsed diseases.

We hypothesize that SF3B1 selectively regulates apoptosis-associated genes, and inhibition of SF3B1 induces cell death in B-ALL cells. We will investigate the role of SF3B1 in B-ALL cell survival, particularly in LICs. We will investigate the therapeutic potential of SF3B1 inhibition, with or without another drugs, both in vitro and in vivo, using our well-established, patient-derived high-risk B-ALL xenograft models.

Understanding the role of RNA splicing in leukemia cell apoptosis in this project has the potential to lead to novel therapeutics to improve overall outcomes by decreasing treatment failure and relapse and has the potential to minimize negative side effects of current treatments by directing the therapy to LICs. Adolescents and young adults with B-ALL have particularly poor outcomes.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Targeting Oncogene-Induced Replication Stress for Neuroblastoma

Campus: UCSD

Principal Investigator: Peter Zage

Start Date: 10/01/2024

End Date: 09/30/2025

Amount: \$85,000

#### Abstract:

Children with high-risk and relapsed neuroblastoma (NB) need improved therapies, and recurrent cytogenetic abnormalities, such as amplification of the MYCN oncogene, represent candidate therapeutic targets. MYCN amplification is associated with significantly worse survival rates for children with NB, and MYCN amplifications in NB can be found both within the linear genome and on circular extrachromosomal DNA (ecDNA). Amplifications of additional oncogenes in NB tumors, such as CDK4 and MDM2, have also been found on ecDNA, suggesting a broad role for ecDNA in NB pathogenesis. MYCN amplification via ecDNA has been linked to the presence of replication stress (RS), and RS is associated with defects in DNA replication and repair and is an important driver of tumor initiation and progression via induction of chromosomal instability. However, the role of RS and its significance as a potential therapeutic target in NB are unknown. We have established that MYCN-amplified NB cells demonstrate significantly increased sensitivity to inhibition of targets that generate increased RS compared to NB cells without MYCN amplification. We hypothesize that enhanced sensitivity of MYCN-amplified NB cells to induction of RS is due to a lethal increase in levels in RS beyond that induced by ecDNA formation and maintenance. Therefore, we propose to evaluate NB cells and tumors for the mechanisms of vulnerability to RS induction. We will investigate the contributions of MYCN amplification and expression and of ecDNA prevalence and content to sensitivity to RS induction in NB and evaluate the roles of MYCN- and ecDNA-induced RS in NB cell and tumor growth and response to treatment. Our proposed research will identify and validate novel approaches for targeting MYCN in NB via the unique strategy of targeting RS in a cancer cell-specific fashion. The proposed research will also facilitate future clinical trials and commercialization of novel inhibitors capable of inducing RS for treating MYCN-amplified NB tumors in need of less toxic and more effective therapies.



**Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

**Self-amplifying mRNA to co-opt anti-viral responses for tumor immune therapy**

*Campus:* UCSD

*Principal Investigator:* Jack Bui

*Start Date:* 10/01/2023

*End Date:* 9/30/2024

*Amount:* \$65,000

*Abstract:*

When viruses infect people, successful elimination of the virus results in the generation of immune cells called memory T cells that persist for years. These memory T cells stand poised to recognize the virus and fight subsequent infection with the same virus. In order to provide optimal protection, memory T cells patrol the body and look for infected cells by examining whether cells have viral pieces, or peptides, on the cell surface. For example, memory T cells that have formed during the COVID-19 (Coronavirus disease 2019) pandemic can recognize pieces of the spike peptide of SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2), the virus that causes COVID-19. Spike-specific memory T cells will kill any cell that expresses viral spike proteins.

Recent findings have shown that memory T cells even patrol tumor tissue. Of course, since tumor cells are not infected with virus, the virus-specific memory T cells that patrol tumor tissue will not harm the tumor cells. Our preliminary studies have found that administration of viral peptides into tumor tissue will make tumors resemble virus-infected cells, resulting in activation of virus-specific memory T cells that can kill the tumor; however, the effect is transient since the viral peptides undergo rapid degradation and clearance. If this response can be augmented and sustained, it could represent an innovative non-toxic approach to tumor immune therapy.

In order to make tumor cells resemble infected cells, we propose to deliver self-amplifying mRNA vaccines into the tumor. These vaccines, similar to Moderna or Pfizer's mRNA vaccines, will result in the production of spike peptides by tumor cells, rendering them immunogenic. Anti-COVID-19 responses will be directed towards the tumor and release tumor antigens to prime tumor-specific responses. We will test our approach using mouse models of viral infection and blood from COVID-19 patients known to have memory T cells specific for spike peptides. If successful, our approach could work in a majority of the world's population given the incredible T cell memory that has emerged from the COVID-19 pandemic.

## **Identifying Disparities in Autologous HCT Utilization for DLBCL in California**

*Campus:* UCD

*Principal Investigator:* Naseem Esteghamat

*Start Date:* 10/01/2023

*End Date:* 9/30/2024

*Amount:* \$74,929

*Abstract:*

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, which is fatal without treatment, but potentially curable with current therapies. The standard of care for patients who relapse or have refractory (R/R) DLBCL >12 months after initial treatment is an autologous, or in some instances, an allogeneic hematopoietic cell transplant (HCT). For patients who relapse <12 months after first-line therapy, HCT is still an option, with the addition of chimeric antigen T-cell therapy more recently becoming a standard of care treatment in this setting. Patients often receive second and further lines of chemo-immunotherapy for disease control for R/R DLBCL, but without HCT, all therapies are palliative in nature.

The utilization of HCT in patients with DLBCL remains low for certain patients and can be impacted by multiple factors, such as access to a transplant center and insurance status. Prior studies have found racial/ethnic disparities in the utilization of autologous HCT in lymphoma patients, with Non-Hispanic Black patients undergoing HCT less often than their Non-Hispanic White counterparts and having inferior survival. To date, little is known about the influence of sociodemographic and clinical factors on HCT utilization for patients with lymphoma over time.

In order to identify barriers to care in patients with DLBCL, we propose a retrospective cohort study of all DLBCL patients diagnosed in California from 1992 to 2016 using a novel data linkage from the Center for International Blood and Marrow Transplant Research (CIBMTR), California Cancer Registry (CCR), and statewide hospitalization data. A study in multiple myeloma patients from this linkage has identified that each of the three data sources independently capture HCT utilization, permitting the assessment of utilization of HCT at the population-level. These data sources also include sociodemographic factors (race/ethnicity, health insurance status, neighborhood socioeconomic status, sex, and age at diagnosis) and clinical factors (e.g., chemo-immunotherapy, disease stage, and comorbidities). This study will identify changes in sociodemographic and clinical associations with HCT over time and inform strategies to help to improve HCT rates, which is a curative therapy for patients with R/R DLBCL.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

# Influence of growth hormones and mechanical loading on osteosarcoma progression

Campus: UCD

Principal Investigator: Kent Leach

Start Date: 10/01/2023

End Date: 9/30/2024

Amount: \$75,000

### Abstract:

Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and young adults. Adjuvant chemotherapy and surgical resection has been used to treat OS for decades, with 5-year survival rates of 60-70%. Unfortunately, for those patients with metastatic disease, 5-year survival rates are dismal (less than 30%), motivating the urgent need to understand what triggers the migration of OS cells from the bone into surrounding tissue, and eventually distant metastasis to the lungs.

When studied in monolayer culture, cancer cells are deprived of their native microenvironment and lose the tumor phenotype, making their responsiveness to therapy inaccurate. Animal models, considered essential for cancer research, also fail to accurately predict clinical outcomes. Tumor features have been created in biomaterials to model both the structural and cellular composition of the bone and marrow microenvironments. Mechanical stimuli also play a key role in tissue development and diseases such as cancer. For instance, OS thrives in a mechanically active microenvironment, especially during the teenage growth spurt. This suggests there may be a link between mechanical signaling, bone growth, and tumor formation that merits further study.

We hypothesize that OS progression and metastatic potential will be increased with exposure to pubescent growth hormones and mechanical loading. Murine OS cell lines or MC3T3 pre-osteoblasts will be entrapped in engineered constructs mimicking the composition and structure of bone marrow. Constructs will undergo dynamic compressive loading in a bioreactor for 2 h per day for 7 days in complete media or media supplemented with testosterone,  $\beta$ -Estradiol, or dihydrotestosterone. We will measure changes in bone formation and known metastatic signaling pathways by standard biochemical assays (e.g., PCR, RNAseq, IHC), while metastatic potential will be examined by tracking metastasis to the lungs upon murine subcutaneous implantation. We will also test efficacy of known chemotherapeutic drugs (i.e., doxorubicin) on stimulated constructs both in vitro and in vivo. The results will reveal the synergy of mechanical signaling on tumor growth in the presence of growth hormones and establish the importance of mechanical loading as potential drug targets to slow the growth and metastasis of OS.

## **Exploring pathways for fetal programming of offspring cancer risk through prenatal diet**

*Campus:* UCI

*Principal Investigator:* Karen Lindsay

*Start Date:* 10/01/2023

*End Date:* 9/30/2024

*Amount:* \$85,000

*Abstract:*

The objective of the proposed research is to investigate the contribution of maternal diet and glucose-insulin homeostasis in pregnancy to offspring cancer risk via dysregulation of the insulin-like growth factor (IGF) axis. Maternal obesity and high birth weight are repeatedly associated with various cancers in children and adults. The IGF axis has been highlighted as a plausible underlying mechanism given that i) IGF-1 and IGF-2 are present in fetal circulation and play key roles in fetal growth and development; ii) IGF-1 is strongly positively correlated with fetal growth and birth weight; and iii) the IGF axis is implicated in the pathogenesis and progression of different types of human cancer such as colon, breast, prostate, lung and leukemia. Early-life efforts for cancer prevention may therefore begin in utero through modulation of the fetal IGF axis, which is thought to be stimulated by circulating glucose and insulin. Maternal diet may be a key modifiable factor via its influence on glucose tolerance.

We propose a prospective observational study of N=80 pregnant women with pre-pregnancy overweight or obesity and diverse racial/ethnic backgrounds, leveraging the high proportion of Hispanic and Asian women who obtain prenatal care at the UCI medical center. Maternal diet in each trimester will be assessed using two 24-hour dietary recalls and the Alternative Healthy Eating Index for Pregnancy will be computed as a measure of diet quality. At 28 weeks' gestation, maternal fasting glucose, insulin, and c-peptide will be measured and the homeostasis model assessment of insulin resistance computed. Maternal glucose concentrations from the standard glucose challenge test will be abstracted from medical record. Neonatal IGF-1, IGF-2, IGFBP-1, and IGFBP-3 will be assayed from cord blood. The separate and combined contribution of maternal diet and glucose-insulin homeostasis to variation in concentrations of cord blood IGFs and IGFBPs will be analyzed, with trimester-specific analysis for the effects of maternal diet. Analyses will be adjusted for maternal demographics, gestational weight gain, infant sex, and gestational age at birth.

It is expected that this study will generate novel preliminary data to test if modifiable gestational exposures may influence offspring IGF axis, representing a possible early-life window for cancer prevention efforts.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### A feasibility study of remote diet-related small habits intervention in cancer survivors

Campus: UCI

Principal Investigator: Yunxia Lu

Start Date: 10/01/2023

End Date: 9/30/2024

Amount: \$85,000

#### Abstract:

The number of cancer survivors in the United States has been rising exponentially, with a projection of 22.2 million by 2030. Adherence to general healthy dietary recommendations, e.g., achieving a healthy body weight, being physically active, and following a dietary pattern rich in whole grains, fruits, and vegetables, has been associated with improved survival and health-related quality of life in cancer survivors. However, previous studies have found low adherence to these guidelines in cancer survivors. Dietary recommendations designed specifically for cancer patients are often based on inclusive, conflicting, or non-existing medical evidence, which is the primary source of confusion and frustration. We intend to design a randomized controlled trial which is an individualized diet-related small habits (DISHs) intervention program for cancer survivors. In the main trial, individual-tailed DISHs will be proposed based on an assessment of DISH perceptions, diet and nutrition status, demographics, and environmental information. The personalized intervention will be implemented remotely through a smartphone App. As more data is collected by the App to train machine learning algorithms (MLA) models, the DISHs intervention will be further modulated individually to increase adherence. The objective of the current study is to examine the feasibility of the main trial. In this study, we will estimate the capability of recruitment of CCCS (clinically cured cancer survivors) in communities through different sources; evaluate questionnaires for measuring DISHs perception and collecting of data that are associated with barriers to unhealthy dietary behaviors; assess questionnaires for measuring adherence of DISHs; investigate the approach to collect biological specimens; evaluate the performance of training the MLA models for personalized DISHs; and ultimately estimate the cost, time and manpower as a whole. The results of this feasibility study will provide solid evidence to design the main trail at the next stage.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

# Small Molecule Inhibition of GNAS; Creating the First Targeted Treatments for Appendix Cancer

Campus: UCSD

Principal Investigator: Dionicio Siegel

Start Date: 10/01/2023

End Date: 9/30/2024

Amount: \$85,000

### Abstract:

The G $\alpha$  protein GNAS, which encodes for the heterotrimeric G protein G $\alpha$ s, is the second most frequently mutated gene in mucinous appendiceal adenocarcinoma (AA) (~50% of tumors) and Pseudomyxoma Peritonei (PMP, ~75% of tumors) and third most common in non-mucinous AA (~25% of tumors), making it a promising drug target in this orphan disease. Although classically druggable, no commercially available inhibitors of G $\alpha$ s exist. Here, we propose an innovative approach to develop and characterize chemical inhibitors of G $\alpha$ s. Given prior in vitro and in vivo data demonstrating that GNAS knockout is lethal to GNASR201 tumors, there is a high likelihood that chemical inhibition of G $\alpha$ s will be an effective therapeutic strategy for GNASR201 mutant tumors.

New Treatments are Needed for Appendiceal Cancer, Currently an Orphan Disease.

Appendiceal tumors encompass a rare and diverse group of neoplasms; AA is the most common histologic subtype. Epidemiologic studies based on Surveillance, Epidemiology, and End Results (SEER) data have shown a steady increase in incidence from approximately 0.2 cases per 100,000 in the 1970s, to current estimates of just over 1 per 100,000. In comparison, this is 40-fold less common than colon cancer, which in the US has an incidence of approximately 40 per 100,000. Cases of early-onset AA, defined as diagnosis before age 50, have increased by 24% between 2011 to 2016, and in 2016 represented 40% of all appendiceal cancer. In contrast, the increase in early-onset colorectal cancer (CRC) was only 2.2% for that same time period. Historically, appendiceal tumors have been grouped together with CRCs, and as of 2021 the National Comprehensive Cancer Network (NCCN) guidelines still suggested that appendiceal tumors be treated with chemotherapy similarly to colon tumors. The rarity of AA has made it difficult to conduct clinical trials, and in the absence of trial data, the NCCN guidelines assume biological similarity due to anatomic vicinity, common embryological origin, and common expression of the transcription factor CDX2. However, there is a growing consensus that AA is a clinically and molecularly distinct entity from CRC, and that AA specific therapies (none exist currently) need to be developed. We have discovered two druggable sites on GNAS and have developed small molecule inhibitors targeting the site next to the point of mutation.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Heparan Sulfate Biomarker for Pancreatic Cancer**

*Host Campus:* San Diego

*Lead Investigator:* Jeffrey Esko

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$75,000

*Abstract:*

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer. This is in part due to difficulties in diagnosing the patients early where intervention would still be effective. Thus, PDAC specific markers that arise early in the disease are in high demand, to develop functional screening methods for early diagnosis. One of the key components to the cancer associated extracellular matrix is a type of carbohydrate, or glycan, called heparan sulfate (HS). HS biology is complex, but it is clear that these molecules accumulate and are structurally altered in many types of cancer. We have found that a unique type of HS, that is found in clinical heparin but rare in healthy tissue, accumulates in early stages of progression to PDAC. This type of HS is called HSAT. Notably, we show that the enzyme that produces HSAT, is elevated in early stages of the disease and correlates with poor disease prognosis. We show preliminary data that HSAT can be detected in PDAC precursor lesions and cancer tissue specimens and that it can be found circulating in the plasma from PDAC patients. We also show preliminary data that HSAT can be used as a target for cancer tracing studies. This project aims to fully investigate the potential of HSAT as a tool for the early diagnosis of PDAC, and potentially pave the way for the investigation of HSAT as a target for directed therapy against PDAC. The discovery of novel markers specific to PDAC has the potential to provide diagnostic and therapeutic strategies to combat this devastating disease, to the benefit of patients worldwide.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Decoding Cancer Acquired Drug Resistance

*Host Campus:* San Diego

*Lead Investigator:* Matthew Hangauer

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$75,000

*Abstract:*

The process by which initially drug sensitive tumor cells acquire drug resistance is poorly understood, but it is widely appreciated that the acquisition of resistance-conferring genetic mutations contributes to acquired cancer drug resistance in patients. The molecular mechanisms underlying the emergence of these mutations are not known. We and others have reported on a subpopulation of cancer cells termed “persister” cells, found within every solid tumor type thus far tested, which enter a quiescent pro-survival state in response to therapy and provide a surviving cancer cell reservoir from which overtly drug resistant tumors can subsequently emerge (e.g. Hangauer MJ et al., Nature 2017, 551, 247). These persister cells initially survive treatment through a reversible, non-genetic mechanism of drug-tolerance which is poorly understood. However, during prolonged treatment, it has been observed that a fraction of persister cells acquire new resistance-conferring mutations which allow for outgrowth of drug resistant cancer cells. It is not understood how persister cells acquire mutations. We recently discovered that during oncogene-targeted therapy treatment, persister cells undergo sublethal apoptotic signaling resulting in activation of apoptotic DNase DFFB which induces DNA damage and mutagenesis. While this exciting discovery points toward a potential new paradigm for how targeted therapy can produce mutations in cancer cells, it is not known whether sublethal apoptotic signaling and DFFB contribute to mutagenesis in other treatment modalities including chemotherapy, antibody treatments and immunotherapy. Here, we address these three distinct treatment modalities. In Aim 1, we will determine whether DFFB is required for chemotherapy- or antibody-induced mutagenesis in persister cells and acquired resistance. In Aim 2, we will determine whether DFFB is required for persister cell antigen loss during acquired resistance to CD8 T cell attack. Together, these proposed experiments will start a new direction of research into the role of DFFB in therapy-induced mutagenesis in persister cells and acquired resistance.



## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Evaluation of ketogenic diet strategies for pancreatic cancer-associated cachexia**

*Host Campus:* Davis

*Lead Investigator:* Gerardo Mackenzie

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$85,000

#### ***Abstract:***

Ketogenic diets (KDs) are diets characterized by having a high fat content and very low or almost no carbohydrates (sugars). Our proposed research studied the role of a KD in pancreatic cancer (PC). PC is a deadly disease, with limited effective treatments. At the time of diagnosis, around 80% of PC patients suffer from cachexia, a condition that involves progressive weight loss, nutritional deterioration and loss of muscle mass. Therefore, new strategies to improve patients' survival and quality of life are urgently needed. Our proposed research evaluated the role of a KD in PC. In particular, we investigated if a KD could improve the quality of life and help prevent cachexia. We observed that mice (that had PC) fed a strict KD had significantly improved motor mass and function compared to mice fed a control diet. We also evaluated exactly how this happens and whether other KD strategies are useful for PC-associated cachexia. We observed that a KD affected muscle physiology in mice that have pancreatic tumors by affecting cellular mechanisms related to muscle strengths. These included decreased muscle inflammation, and increased activation of the protein eIF2 $\alpha$ , which regulates many processes related to muscle generation. These studies, which have been recently published, strongly indicate that a KD might to be a beneficial dietary treatment for PC-induced cachexia. In addition, since strict diets are difficult to maintain throughout cancer treatment, we are currently running a study to test if intermittent feeding of a KD (i.e: feeding a KD for a week following for a week of control diet) can achieve similar effects as observed with the strict KD. This part of the work is currently ongoing. The successful completion of our studies could inform us on whether certain diets, such as the KD, can be beneficial for PC and for mitigate cancer cachexia, which is a major problem experienced by PC patients.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Integrated Model of Cancer, Vasculature, and Immune System**

*Host Campus:* Merced

*Lead Investigator:* Kara McCloskey

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$85,000

*Abstract:*

Endothelial cells (ECs) are activated to generate new blood vessels that play a key role in supporting the growth and spread of many cancers. However, treatments shown to be highly effective in mice are proving less robust in humans. Three-dimensional microfluidic chips enable recapitulation of the tumor microenvironment with human cancers, human endothelial cells and human immune cells. Establishing a highly angiogenic tumor vasculature perfused with immune cells is needed to accurately reconstruct the tumor pathology. Our laboratory has identified and characterized a unique highly angiogenic ECs from mouse and human embryonic stem cells (ESC). The proposed studies will examine various cancer spheroids' ability to recruit new blood vessels, undergo metastasis, and examine response to anti-angiogenic drugs for treating growing cancers.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Flexible Robotic Evacuator for Minimally Invasive Brain Tumor Therapy

*Host Campus:* Riverside

*Lead Investigator:* Jun Sheng

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$85,000

*Abstract:*

The goal of this project is to design, fabricate, and test a flexible robotic evacuator that can be deployed by meso-scale steerable robots inside a brain tumor and controlled to evacuate tumor tissue at multiple locations towards conformal tumor evacuation. Glioblastoma multiforme (GBM) is one of the most challenging cancers to cure. Each year, nearly 12,000 new cases of GBM are diagnosed in the US, with the overall median survival being only 12 to 18 months. GBM rarely metastasizes to other organs; however, standard therapies with surgery via a craniotomy combined with adjuvant radiation and FDA-approved drugs can barely prevent the recurrence of GBM. For recurrent GBM (rGBM), although re-surgery can provide the best survival on select patients, most patients cannot afford re-surgery due to their generally poor health conditions. Thus, minimally invasive techniques arise to address this challenge. Nevertheless, existing tools are straight and rigid, and thus are not adequate to remove large and irregularly shaped tumors. Hence, there is an urgent need to develop a steerable robot that can be introduced through a small burr hole and manipulated throughout the tumor to remove the tumor in a minimally invasive manner. This project aims to develop and demonstrate a flexible robotic evacuator that can be integrated with steerable neurosurgical robots. The device will be made of flexible material so that it can be delivered through the curved channel of a steerable robot. In this project, we will: 1) design and fabricate a flexible robotic evacuator with a capability of aspiration and irrigation, 2) Integrate the evacuator with a steerable robot, and 3) evaluate the functionality of the robot system. With the success of this pilot project, we will pursue a NIH RO1 grant to improve the robot design, develop a planning and control system, and perform in vivo studies on normal and GBM pigs.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Enhancing Online Group Fitness Exercise for Health Improvement for Patients with Cancers**

*Host Campus:* Riverside

*Lead Investigator:* Hao-Chuan Wang

*Start Date:* 10/1/2022    *End Date:* 9/30/2023    *Amount:* \$85,000

*Abstract:*

Zumba and similar group-based aerobic exercises have become popular worldwide, engaging approximately 12 million people to attend the fitness dancing parties on a frequent basis. Prior studies showed evidential benefits in mental and physical wellness, as well as quality of life, of such fitness programs among the common public and patients with cancers. Patients with cancers, either on treatment or off therapy, may encounter challenges to attend in-person training due to their illness and mobility constraints, in addition to the current global covid pandemic. Therefore, it's essential to explore online options which offers easy accessibility and inclusiveness of "exercise classes". In terms of personal motivation and social engagement, patients with cancers may also benefit from additional personalization and social support to help them physically catch up with the exercise and socially connect with co-trainees. Our goal in this project is to create a social, accessible and inclusive video-mediated Zumba experience that extends the benefits of group training to the online space (Zumba together!). By enhancing video communication, we will develop a real-time action feedback mechanism and a recommendation mechanism that produces recommendations of training content and co-trainees, both driven by continuous comparison of pose estimations performed by the system using a data-driven machine learning model, with the goal to improve social synchrony and engagement in the virtual program. In this one-year project, we will design and prototype the technological mechanisms and conduct a pilot study with up to 30 health adults to assess the feasibility and benefits of using the enhanced video communication channel for virtual group exercises. The results from this project will be used to apply for an R01 to conduct a multicenter clinical trial targeting young adult cancer survivors and patients undergoing treatment.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

# Electrical Impedance Spectroscopy for Monitoring the Chemoresistance of Prostate Cancer Cells

Host Campus: Irvine

Lead Investigator: Tayloria Adams

Start Date: 10/1/2021    End Date: 9/30/2022    Amount: \$ 85,000

### Abstract:

Prostate cancer is a life altering disease that affects one in six men in the United States. A challenge in treating prostate cancer cells is overcoming their plasticity. Cancer cells have subpopulations of stem cells that can switch phenotypes, converting between chemoresistant and non-chemoresistant cells. In particular, the epithelial mesenchymal transition (EMT) is linked to chemoresistance and the presence of cancer stem cells. EMT is a reversible process in which cells lose their epithelial features and gain mesenchymal features. The goal of this proposal is to monitor EMT to gain a deeper understanding of chemoresistant cells and the time scale at which change occurs. A custom electrode-based microfluidic device will be used to measure dynamic changes in impedance at the single cell level. Electrical impedance spectroscopy is a cell analysis technique that offers a label-free approach for the recognition of cancer cells, their dynamics, and chemoresistance using electric fields.

Our central hypothesis is that impedance is a good candidate for the detection of prostate cancer cells' EMT, which is associated with the presence of cancer stem cells. We have preliminary data that indicates impedance detects: (a) stages of prostate cancer cells, stage 4 (PC-3) and stage 1 (DU145) and (b) phenotype differences in PC-3 and DU145 cells cultured as monolayer (less chemoresistant) versus suspension (more chemoresistant). Also, we have found correlations between impedance and the gene expression of N-cadherin, E-cadherin, and ZO-1 proteins (markers of EMT).

The following aims will be tested, Aim 1: Characterize the baseline impedance spectra and functional profile of PC-3, DU145, LnCAP and patient samples. Aim 2: Modulate the EMT of PC-3, DU145, LnCAP and patient samples using transforming growth factor b (TGF-b), hypoxia inducible factor 1 alpha subunit (HIF-1a), and estrogen receptor alpha (ER-a) and quantify the impedance spectra and functional profile. Impedance measurements will be coupled with cell proliferation, cell cycle analysis, apoptosis, and gene expression assays.

At the end of these studies impedance and membrane capacitance will be quantified and screened as potential biomarkers of EMT. This work will lay the foundation toward the development of potential EMT-specific drug therapies for prostate cancer.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Evaluating cost effective care for differentiated thyroid cancer**

*Host Campus:* Davis

*Lead Investigator:* Michael Campbell

*Start Date:* 10/1/2021    *End Date:* 9/30/2022    *Amount:* \$ 75,000

*Abstract:*

Thyroid cancer is one of the most common cancers in the United States and its incidence is increasing. Total thyroidectomy (removal of the thyroid gland) is the predominant treatment for thyroid cancer but carries the risk of hypoparathyroidism because of damage to the parathyroid glands (small organs that lay adjacent to the thyroid and are responsible for calcium homeostasis). Hypoparathyroidism is the most common complication following thyroidectomy and is responsible for the majority of emergency department (ED) visits and readmissions following surgery. The propensity for thyroid cancer to present in young populations, coupled with its good prognosis, increases the importance delivering safe, cost effective care for these patients. Complications of treatment, such as hypoparathyroidism, can debilitate patients for many years, and the economic impacts of these complications must be paid for by society for decades after they are incurred.

The purpose of this study is to use California Cancer Registry (CCR) and Office of Statewide Health Planning and Development (OSHPD) databases to: 1) assess the incidence of hypoparathyroidism in patients undergoing thyroidectomy for thyroid cancer and determine factors, including racial/ethnic and socioeconomic disparities, associated with hypoparathyroidism and 2) calculate hospitalization and ED costs associated with hypoparathyroidism

To accomplish these objectives, we will identify patients with thyroid cancer who underwent a thyroidectomy between 2005 - 2018 in California using the CCR. Hospital readmission and ED discharge diagnoses will be obtained from the OSHPD databases. Patient data from the CCR and OSHPD will be linked to evaluate the incidence, risk factors, treatment disparities, and costs associated with hypoparathyroidism following thyroidectomy for thyroid cancer. We expect the findings of this study will provide the data to help establish programs to assure quality, equitable thyroid cancer care for all patients in California, including the economically underserved and racial/ethnic minorities.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Etiology of Ph-like ALL and the mechanisms driving Latinx cancer disparities

Host Campus: Irvine

Lead Investigator: Nicholas Pannunzio

Start Date: 10/1/2021 End Date: 9/30/2022 Amount: \$ 84,990

#### Abstract:

Philadelphia chromosome-like B cell acute lymphoblastic leukemia (Ph-like ALL) is an ALL subtype that disproportionately affects the Latin community and is characterized as having a poor response to therapy, a high risk of relapse, and a peak onset in adolescents and young adults. While lacking a BCR-ABL fusion, nearly 65% of Ph-like ALL cases carry a rearrangement in the cytokine receptor-like factor 2 (CRLF2) gene located on both X and Y chromosomes, the most common being a chromosomal translocation with the immunoglobulin heavy chain locus (CRLF2-IgH) resulting in increased and uncontrolled expression of CRLF2 that correlates with reduced survival. CRLF2 rearrangements are significantly higher in patients of Latin descent, indicating this is a high-risk group for Ph-like ALL and that understanding the molecular mechanisms driving CRLF2 rearrangements would greatly benefit prediction and diagnosis of Ph-like ALL. Our recent analysis of over 2,000 translocation breakpoints in human patients revealed that DNA double-strand-breaks (DSBs) that initiate the CRLF2-IgH translocations can occur within a 25 kb region upstream of the gene but are enriched 36-fold in a 311 bp cluster region and involve the B cell-specific mutator activation-induced cytidine deaminase (AID). Tight clustering of breakpoints indicates a non-random mechanism underlying DSB formation and elucidation of this mechanism would fill a crucial knowledge gap regarding the etiology of Ph-like ALL. Our central hypothesis is that CRLF2 DSBs occur through a defined mechanism that involves abnormal AID levels in an early pre-B cell stage and altered epigenetics that makes AID a more potent mutator and DSB initiator. Our hypothesis will be tested by pursuing two specific aims: (1) Use our novel molecular assay to determine the mechanism of CRLF2-IgH translocations and (2) Compare the genomic DNA from B cells of Latino and non-Latino populations for genetic and epigenetic risk markers linked to CRLF2 rearrangements. This work is significant as it will allow us to both address cancer disparities in the Latino community and develop novel diagnostics applicable to several B cell malignancies in wider population studies.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Cancer therapeutics via small molecule-mediated p53 mutant reactivation

*Host Campus:* Irvine

*Lead Investigator:* Feng Qiao

*Start Date:* 10/1/2021    *End Date:* 9/30/2022    *Amount:* \$ 75,000

*Abstract:*

About 600,000 new cancer patients in the United States are diagnosed each year with tumors expressing mutated p53. These cancers express full length p53 that has lost tumor suppressor activity but acquired gain-of-function oncomorphic properties that provide selective advantage to cancer cells. The large number of affected cancers make p53 an exquisite target for cancer therapy. However, therapeutic approaches require reactivation of mutated p53, which in itself is challenging. Reactivation of mutant p53 is possible through both intragenic second site mutations and small molecules that induce a conformational change and stabilize an active conformation of p53 hotspot mutants. We have developed a compound series that binds mutant p53 and thereby restores DNA binding activity of mutant p53 in a reconstituted purified in vitro system. Furthermore, cell proliferation is halted, and apoptosis is induced in a p53 mutant dependent manner. Importantly, growth of tumors carrying p53 mutants is blocked by this compound series in animal models. These compounds provide strong support for feasibility to develop drug-like molecules that can restore tumor suppressor activity in p53 hotspot mutants. However, these compounds act in the micromolar range and moving from these preclinical successes towards the bedside requires more lead compound series with diverse chemistry, and most importantly, a better understanding of the mechanisms underlying p53 mutant reactivation as well as the identification of key features that determine potency of tumor suppression in the reactivation process. We propose to develop such mechanistic understanding by detailed characterization of p53 hotspot mutant reactivation by small molecules as well as second site mutations. The proposal will generate molecular understanding of key features that allow reactivation of tumor suppression activity of p53 cancer mutants. Such understanding will help the identification of new p53 reactivation lead compounds in the future. The therapeutic concept of p53 mutant reactivation could transform treatment for many cancer patients, but lack of experience with reactivation drug development makes it difficult to achieve this goal. Building detailed molecular knowledge about the reactivation process will overcome these current roadblocks.



## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Outcomes for premenopausal women with triple negative secondary breast cancer

Host Campus: Davis

Lead Investigator: Candice Sauder

Start Date: 10/1/2021 End Date: 9/30/2022 Amount: \$ 75,000

#### Abstract:

In the adolescent and young adult (AYA; 15-39 years) female population, breast cancer (BC) is the most common cause of cancer-related death. Overall, in premenopausal women under 50 years of age, BC is more likely to be tumor marker receptor negative (estrogen, progesterone, and human epidermal growth factor 2 receptor negative, i.e. triple negative), of higher grade, and diagnosed at more advanced stages--all factors associated with worse survival. In addition, multiple studies have shown that the AYA population has the highest absolute excess risk for secondary malignancies of any age group, including most commonly BC. Our prior work comparing primary and secondary BCs in premenopausal women has identified that secondary BCs present at earlier stages and tend to be lymph node negative. However, even with diagnosis at an earlier stage and accounting for tumor receptors and grade, being diagnosed with a secondary BC was associated with worse survival compared to a primary BC. Non-Hispanic Black women experience the worst prognosis after both primary and secondary BC.

Traditionally, early stage BC is treated with different adjuvant therapies than more advanced staged BC. Chemotherapy is used less frequently, as is radiation. However, because early stage secondary BC has worse survival than early stage primary BC, treatment for secondary BC may need to differ or be more aggressive. Currently there are no guidelines that define or differentiate treatment for primary and secondary BC, leading to the important question of whether differences in treatment contribute to the survival disparities. Additionally, no study to date has assessed treatment, especially chemotherapy regimens utilized in young women with primary and secondary BCs, to determine treatment differences and the impact on survival.

We propose extracting treatment data, including chemotherapy regimen data via the text fields, from the California Cancer Registry for premenopausal women diagnosed with triple negative BC, a significantly increased aggressive form of BC found in both the primary and secondary BC population. By determining the impact of these regimens on BC survival overall and by race/ethnicity and age group, we will identify areas for intervention to improve outcomes and reduce survival disparities in premenopausal patients with secondary triple negative BC.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Neurocognitive Processes for Mammographic Detection of Breast Cancer**

*Host Campus:* Riverside

*Lead Investigator:* Weiwei Zhang

*Start Date:* 10/1/2021    *End Date:* 9/30/2022    *Amount:* \$ 85,000

*Abstract:*

Understanding the nature of medical expertise in cancer diagnostics imaging could be fundamental for cancer diagnostics, clinical training, and development of computer aided detection programs. This project is aiming at directly assessing the characteristics of underlying neurocognitive processes for medical expertise in cancer diagnostics imaging. Specifically it is hypothesized that two dissociable cognitive processes (discrete processing of focal lesions and continuous holistic processing) jointly support mammogram diagnostics, the dual-process hypothesis. We will use a combination of novel behavioral paradigms, individual differences, computational, and MRI methods to assess three key predictions of the dual-process hypothesis. First, expertise in mammogram reporting (e.g., mammographers as opposed to medical students) should manifest more in “gist” information, as opposed to focal information, that can be extracted from mammogram images. Second, processing of holistic mammogram image features should occur earlier than detection of local signs of cancer. Third, acquisition of the processing of holistic mammogram image features should manifest in the Fusiform Face Area of the brain, but in asymmetrical way. The project will develop a novel Hierarchical Bayesian method to assess dissociable cognitive processes underlying mammogram reporting (Aim 1), which will be used in conjunction with a novel experimental paradigm to assess the neural mechanisms (Aim 2) for mammogram reporting. Some pilot data collected in a NIH funded Medical Perception Lab at the 2019 Annual Conference of Radiological Society of North America has provided preliminary support for the central hypothesis.

We have developed an interdisciplinary team with the experimental, computational/analytic, neuroimaging, and clinical expertise for the proposed research. The UC CRCC seed grant will support the team to develop subject recruitment mechanism for the targeted enrollment of the specific subject populations, collect pilot data, and establish feasibility for future grant applications. The long-term goals of the project are to further our understanding of medical expertise, to provide the theoretical footing for computer aided medical diagnostic programs, and to develop medical training components that target the core neurocognitive processes.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Effects of tobacco and cannabis policy implementation on consumption**

*Host Campus:* Davis

*Lead Investigator:* Dorothy Apollonio

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$ 51,454

*Abstract:*

Between 2016 and 2018, California changed multiple policies addressing substance use by legalizing recreational use of cannabis, increasing the minimum age of legal access for tobacco to 21 years, regulating electronic nicotine delivery systems as tobacco products, and expanding access to treatment. The extent to which cannabis policies would be implemented was left to local governments, and varies significantly within the state, with some counties banning retail sales while others allow broad commercialization. As a result, the public health impacts of these changes have been difficult to assess. In particular, stricter tobacco control policies intended to reduce cancer risk may be affected by increased access to cannabis, leading to increased co-use, tobacco-to-cannabis substitution, or both at once in different subpopulations. In this pilot study, we propose to classify tobacco and cannabis policies in California counties and identify associated consumption patterns. We hypothesize that local policies can be classified by the degree to which they restrict access and subsidize treatment, and that policies that do so are associated with reduced consumption of both tobacco and cannabis. We propose the following aims: 1) Map local tobacco and cannabis policies in California and classify their comprehensiveness; and 2) Determine the association between local policies and tobacco and cannabis consumption patterns. We will collect policy data for California counties using data collected by the American Nonsmokers Rights Foundation (ANRF; tobacco) and the Orange County Register (cannabis). We will classify local policies by the degree to which they restrict access to and subsidize treatment for tobacco and cannabis, including treatment policies for co-use. Using data from the 2018 California Health Interview Survey (CHIS), we will analyze the association between local policies and health outcomes: 1) past-month tobacco and cannabis use; 2) modes of use (e.g. smoking, vaping, edibles, dissolvables); and 3) co-use of tobacco and cannabis, (both single-occasion and concurrent). California's choice to devolve implementation of cannabis policies to local governments makes it possible to determine how substance use policies interact to change consumption, and will inform governments within and outside California seeking policy interventions to prevent cancer.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Advancing VCP inhibitors as experimental therapeutics in ovarian cancer

Host Campus: Davis

Lead Investigator: Jeremy Chien

Start Date: 10/1/2020 End Date: 9/30/2021 Amount: \$75,000

#### Abstract:

Protein quality control (PQC) pathways are important for protein and organelle homeostasis and essential for the fitness of cancer cells in the face of genomic instability, thus creating a cancer cell dependency. Components of PQC, such as heat shock proteins, also provide an adaptive response to cancer therapy and contribute to resistance. Therefore, PQC represents a point of vulnerability for cancer cells and a therapeutic target to potentiate the efficacy of current cancer therapies. Underscoring this point is a series of reports indicating that various components of PQC are identified as synthetic lethal targets in cancer cells. Among them, valosin-containing protein (VCP, also known as p97 AAA-ATPase) was identified as a lineage-specific dependency gene in ovarian cancer. VCP participates in various cellular functions of protein and organelle homeostasis, and we have shown that VCP inhibition induces ER stress, the terminal unfolded protein response and cytotoxicity in ovarian cancer cells. A previous clinical lead, CB-5083 (CB), inhibits VCP activity in nanomolar concentrations and produces cytotoxicity in over 300 cancer cell lines at low micromolar concentrations. Despite promising in vitro and in vivo anti-cancer activities, a recent first-in-human Phase I clinical trial with CB was stopped due to off-target effects on PDE6, a protein critical for phototransduction, which manifested as ocular side effects. We propose to circumvent the off-target issues using two approaches: (1) nanoformulation of CB to optimize delivery to tumor tissues and (2) the development of CB derivatives as VCP degraders. In the first approach, we will use hydrophobic porphyrin that forms the drug-loadable core with PEG forming the lipid-soluble micelle. Pegylated cross-linked nanoparticles (NPs) are pH-sensitive due to the presence of a Schiff base. In the acidic tumor microenvironment, smaller NPs are released due to the cleavage of the cross-links, thereby limiting drug delivery to the eye. In the second approach, we will synthesize the CB-based VCP degraders using drug design called proteolysis-targeting chimera (PROTAC). These PROTAC molecules can be designed such that it will specifically target VCP but not PDE6 for degradation. These two approaches will overcome current clinical limitations of CB.

**Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

## **Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Latinos with Testicular Cancer**

*Host Campus:* Irvine

*Lead Investigator:* Michael Hoyt

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$85,000

**Abstract:**

Testicular cancer (TC) diagnosis and treatment, especially given its threat to sexuality and reproductive health, can be distressing in young adulthood. In fact, the prevalence of depressive symptoms in TC exceeds the general population, and young Latino men are at high risk for adverse outcomes after treatment. In fact, the majority of young adult cancer survivors will experience impairing, distressing, and modifiable physical, behavioral, and psychosocial adverse outcomes that persist long after the completion of medical treatment. Yet, few targeted, tailored, culturally-relevant interventions exist to assist young Latino survivors in re-negotiating life goals and regulating cancer-related emotions and none focus on reducing cancer burden via biobehavioral mechanisms. Young or “emerging” adulthood is marked by goal attainment. Chronic illness experienced as “off time” in the lifespan interrupts goal pursuits and threatens valued life directions. As young adults return to goal pursuits, re-entry to post-cancer life can be a critical point in the survivorship trajectory. Behavioral intervention at this time is well positioned to confer longer-term impact. Emergent from our group’s preliminary research, we developed and pilot-tested Goal-focused Emotion-Regulation Therapy (GET) as a behavioral intervention to enhance self-regulation through improved goal navigation skills, sense of purpose, and ability to regulate emotional responses in young adults with TC. Responsive the need for feasible, effective, and scalable interventions that meet the need of ethnic minority men, 25 Latino young adults (ages 18-39) with TC will receive 6 sessions of GET. This pilot study aims to establish feasibility, clinically-meaningful (not statistically significant) change, and guidance for cultural adaptation. We predict that GET, and our ability to detect meaningful change, will be feasible in Latino young adult TC survivors. We expect GET to be associated with reduced distress and reductions in adverse biobehavioral indicators (dysregulated stress hormones, elevated inflammation). We also expect that greater endorsement of culturally-relevant factors (i.e., familism, simpatia, acculturation/acculturative stress, machismo/caballerismo) will condition the impact of GET on primary and secondary outcomes and that qualitative data will identify culturally-relevant adaptation.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Epigenetic landscape of DNA methylation in pancreatic cancer progression

*Host Campus:* Davis

*Lead Investigator:* Chang-il Hwang

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$85,000

*Abstract:*

Pancreatic cancer is one of the deadly human malignancies, owing in part due its early onset of metastasis. Key driver mutations for pancreatic cancer metastasis have not been identified, and alteration of epigenetic pathways has been suggested as a potential mechanism. We have established the innovative pancreatic cancer organoid cultures derived from both patients and genetically engineered mouse models. Pancreatic organoid cultures are amenable for genetic manipulations and suitable for high throughput 'omics' approaches, allowing us to dissect the underlying molecular mechanisms. Using the pancreatic organoid models, we have reported that epigenetic reprogramming as a potential factor in pancreatic cancer metastasis. Two major epigenetic changes are histone modifications and DNA methylation. Previously, we have extensively profiled the key histone modifications in pancreatic cancer organoids. However, another key epigenetic regulation, alterations of DNA methylation landscape remains to be determined in pancreatic cancer progression. Here, we propose to profile genome-wide DNA methylation in both human and mouse pancreatic organoid models and identify functionally important epigenetic changes of DNA methylation in metastasis. We have performed the Reduced Representation Bisulfite Sequencing (RRBS) in the murine organoid models for pancreatic cancer. We will investigate how DNA methylation pattern changes in pancreatic cancer progression (normal, PanIN, tumor and metastasis). In addition, we will intersect DNA methylation data with transcriptional profiles and key histone modifications in the promoter and enhancer regions. This will provide mechanistic insights in how differential DNA methylation contributes to gene expression and disease progression. To determine the effect of the differential DNA methylation in individual genes, we will employ CRISPR-dCas-DNMT or -TET system to methylate or demethylate specific regions of interest, respectively. This will enable us to identify functionally important DNA methylation for pancreatic cancer metastasis. In sum, the proposed study will elucidate the epigenetic landscape of DNA methylation in pancreatic cancer progression using pancreatic organoid models. Furthermore, genes associated with differentially methylated regions can be exploited for the development of novel diagnostic and therapeutic strategies.

**Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

## **"Lymphomizing" Treatment of Head and Neck Cancer using Involved Field RT with Chemo-Immunotherapy**

*Host Campus:* San Diego

*Lead Investigator:* Loren Mell

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$82,500

*Abstract:*

Current standard treatment for most advanced head and neck cancers involves combined chemotherapy and radiation therapy. Newer treatment approaches are incorporating immunotherapy, specifically PD1:PD-L1 checkpoint inhibitors, into the standard treatment paradigm. Standard radiation fields cover both the primary tumor plus "elective" radiation to areas of potential regional spread, especially to lymph nodes, even though many patients do not actually have disease present in the nodes. Large radiation fields result in significant acute and long-term morbidity, particularly difficulty swallowing, which can lead to feeding tube dependence and risk of aspiration. In the setting of concurrent immunotherapy, it is not clear that such large fields are required. For example, in the treatment of lymphoma, successive advances in the quality of systemic therapy have permitted both lower radiation doses and, importantly, smaller field sizes (i.e., Involved Field Radiation Therapy, IFRT), drastically decreasing the morbidity of radiation therapy. Moreover, treatment of healthy nodes with radiation could actually be harmful by interfering with the effectiveness of immunotherapy, which is trying to stimulate the anti-tumor immune response and depends on functional lymph nodes. However, prospective trials are needed to confirm that it is safe to treat head/neck cancer patients with IFRT and that this does not lead to excessively high rates of recurrence, which to our knowledge has not been tested. Therefore we propose to treat a pilot cohort of 12 patients with IFRT (radiation directed only at visible disease on positron emission tomography) plus immunotherapy with standard chemotherapy (tri-weekly cisplatin), and prospectively assess for rates of disease recurrence. Secondly, we will collect novel information on swallowing function using quantitative imaging techniques in collaboration with speech and language pathology, and will collect serial blood specimens for comparison with data from previous trials using standard radiation.

## **A polygenic score for prediction of aggressive and fatal prostate cancer in multi-ethnic populations**

*Host Campus:* San Diego

*Lead Investigator:* Tyler Seibert

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$75,000

*Abstract:*

When detected in its early stages, prostate cancer is curable, but it still causes over 350,000 deaths per year. Screening with a blood test to measure prostate-specific antigen (PSA) leads to earlier detection and has been shown to reduce cancer deaths. However, PSA testing of the entire male population leads to many false positives and many diagnoses of slow-growing cancers that are unlikely to cause significant problems. A test is needed to help physicians decide whether a given patient would benefit from screening—and what age to start that screening. Such personalized decisions might be made by measuring each man’s genetic risk for aggressive forms of prostate cancer. A genetic score (called a polygenic hazard score, or PHS) has been developed and tested in a dataset of thousands of men. The PHS was strongly associated with aggressive prostate cancer. While promising, the PHS was developed and validated with only data from men of European ancestry, reflecting data availability at the time.

We have obtained access to a large, multi-ethnic dataset, through collaboration with the international PRACTICAL consortium. We propose here to test the original PHS to see whether it performs well in a new dataset and whether performance is affected by race/ethnicity. Rather than self-reported race/ethnicity, we will use genetic ancestry (European, African, or Asian) determined by the individual’s own DNA. We will evaluate whether PHS is associated with age at diagnosis of aggressive prostate cancer and with lifetime risk of death from prostate cancer. PHS will be compared to family history and other risk factors for prostate cancer. Our preliminary results suggest that the original PHS works in men of multiple racial/ethnic backgrounds, but performance is best in genetic Europeans.

After formally testing the original PHS in each genetic subgroup, we will use the multi-ethnic data to optimize the score for each genetic ancestry. We will do this by searching for genetic markers within each genetic ancestry that are associated with age of onset of prostate cancer and incorporating them into an enhanced PHS.

Ultimately, PHS could guide personalized prostate cancer screening decisions for men of all races/ethnicities, thus saving lives through early detection.



## **Label free, high throughout detection and separation of individual breast cancer stem cells**

*Host Campus:* Irvine

*Lead Investigator:* Zuzanna Siwy

*Start Date:* 10/1/2020    *End Date:* 9/30/2021    *Amount:* \$75,000

**Abstract:**

Cancer stem cells (CSCs) are a rare cellular subset within a tumor (1-5% but in some tumors only up to ~0.01% of the total tissue) that are believed to be responsible for the metastatic progression of cancer, as well as resistance to chemotherapy and radiation therapies, and disease relapse. As such, the successful isolation of viable CSCs with minimal perturbation and manipulation would enable further understanding of CSC biology, which is necessary for the development of novel therapeutics directly targeting this rare subset of aggressive cells. This is especially relevant to breast cancer where 100% of mortality is due to metastasis. The goal of the proposal is to design a microfluidic platform capable of label-free isolation of viable CSCs breast cancer cells from blood and tissue.

CSCs will be separated based on their unique mechanical properties. Identifying the cells using physical and mechanical properties rather than chemical markers makes the platform independent of an a priori knowledge of cells' surface characteristics, which is often unknown. The microfluidic channel we designed contains a cavity flanked by two narrower regions; at all positions along the channel, the channel width is larger than or comparable to the cells' size. The inhomogeneous pressure gradients and shear stress in such a channel cause multiple deformations of the cell in both directions. The new platform will provide characterization of individual cells and allow finding one-to-one correspondence between a given cell's mechanical properties and the same cell's biological function. Hundreds of cells will be analyzed per second, and 5 mL of cells suspension will be analyzed within 15 minutes.

In Aim 1, the cells (MCF-7 and MDA-MB-231) will be characterized by combined optical and electrical signals analyzed by advanced machine learning approaches. Machine learning algorithms will be applied to find direct correspondence between the optical and electric signals, enabling one to characterize cells' deformation based on electrical recordings only.

In Aim 2 we will develop a platform to isolate individual CSCs that can be subjected to further biochemical analysis.

This work will lay the foundation toward the understanding of CSCs, the cancer stem cell model, and the development of potential CSC-specific drug therapies for the treatment of metastatic cancer.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Patterns of Care and Outcomes in AYAs with Germ Cell Tumors

*Host Campus:* Davis

*Lead Investigator:* Elysia Alvarez

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$75,000

*Abstract:*

Germ cell tumors (GCT) are the third most common cancer in adolescent and young adult (AYA: 15-39 years) patients and its incidence is increasing. Survival has increased significantly over the past three decades; however, disparities by stage of disease, age and sociodemographic factors remain. AYA patients with GCTs do not receive uniform care, with providers varying from pediatric oncologists, medical oncologists, urologists, to gynecologists. They also may be treated in community hospitals or specialized cancer centers (SCC: Children’s Oncology Group and National Cancer Institute-designated centers). Treatment at SCCs or by pediatric oncologists has been found to improve outcomes in AYAs with certain cancers (i.e. acute lymphoblastic leukemia, Ewing sarcoma), possibly due to clinical trial enrollment and standardized care approaches, but these associations have not been assessed for AYA patients with GCTs. Most of what is known has been obtained through clinical trials, which while important, does not provide a complete “real world” picture of treatment, location of care and survival outcomes in this patient population. Therefore, we propose to undertake a comprehensive, population-based assessment using the California Cancer Registry (CCR) linked with statewide hospitalization data. This database captures information on nearly all patients with GCT in California—allowing us to determine patterns of care for AYA patients with GCTs. We aim to identify the treatment regimens administered and determine differences by location of cancer treatment and treating physician specialty; and examine the impact of guideline concordant care, location of care and treating physician specialty on survival. We hypothesize that guideline concordant treatment will differ by the treating specialty, especially in older AYAs, and that survival in patients with later stage disease will be superior if these patients are treated at SCCs and/or with guideline concordant care. We will accomplish these aims through the use of novel methods to abstract chemotherapy regimens (protocol, specific drugs), provider subspecialty (urology, oncology etc.) and surgical details (biopsy date, resection date, surgical margins) from text fields in the CCR. Findings from this study will identify potential areas for intervention that can improve survival outcomes in AYA patients with GCTs.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Novel Links Between Wnt Signaling, Centrosomes, and Cancer

*Host Campus:* Irvine

*Lead Investigator:* Lee Bardwell

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$75,000

*Abstract:*

Normal patterns of Wnt signaling are necessary for tissue development and maintenance, while hyperactive Wnt signaling is implicated in many cancers, especially colon cancer. Indeed, loss of the Wnt pathway negative regulator adenomatous polyposis coli (APC) is typically an early step in the progression of colon cancers. APC loss results in the stabilization of beta-catenin, which then forms active heterodimers with LEF/TCF (lymphoid enhancer factor/T-cell factor) transcription factors. LEF/TCF target genes promote proliferation, migration, Warburg-type metabolism, and survival, all of which contribute to malignancy.

Our preliminary experiments have uncovered intriguing new connections between the Wnt signaling pathway and the centrosome, the major organizer of the microtubule cytoskeleton in mammalian cells. Specifically, we have found that LEF/TCF transcription factors localize to the centrosome, where they interact with the centrosomal scaffold protein CEP152, and with the protein kinase PLK4. Furthermore, our preliminary studies indicate that PLK4 phosphorylates the TCF1 protein and regulates the expression of LEF/TCF target genes. The centrosome is critical for the maintenance of genome integrity, and the PLK4 protein kinase is the master regulator of centrosome duplication, whose over- or under-expression causes tumor-promoting chromosomal instability. Thus, our findings suggest potential new connections between Wnt signaling and the maintenance of genome stability.

We propose a series of experiments to determine the mechanism and functional consequences of the centrosomal localization of LEF/TCF transcription factors, and of the phosphoregulation of LEF/TCF factors by PLK4.

We will determine the domain of CEP152 that binds to LEF/TCF transcriptional factors and the functional consequences of this interaction. In addition, we will map the site(s) of PLK4-mediated phosphorylation of TCF transcription factors, and investigate the functional consequence of this phosphorylation

The potential impact of the studies proposed herein is considerable. Our research could reveal new therapeutic opportunities for targeting the Wnt pathway, unexpected new connections between Wnt signaling and the maintenance of genome stability, and a novel mechanism by which the centrosome may communicate with the nucleus to regulate gene expression.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Detecting tumor-specific exosomes on a chip

*Host Campus:* Davis

*Lead Investigator:* J. Sebastian Gomez Diaz

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$74,999

*Abstract:*

Sensitive detection of circulating tumor-associated exosomes (TEXs) and related extracellular vesicles (EVs) may improve strategies for ovarian cancer (OvCa) detection and monitoring because (i) they represent stable and protected biomarkers in blood circulation and (ii) their composition, including surface protein markers, is tissue and pathology-specific. To achieve the best sensitivity for detecting low-frequency TEXs in early stage cancer patients, innovative high-resolution tools are needed. The cornerstone of this multidisciplinary project is to develop an extremely sensitive and affordable on-chip bio-sensing platform able to accurately detect the presence of EVs including TEXs in microseconds, with crucial implications for early detection of OvCa. We have previously demonstrated that our sensor, which relies on a novel transduction mechanism that merges tailored optical and nanomechanical resonances, outperforms at room temperature the sensitivity of the best commercial FTIRs over a narrowband, and here propose to apply this novel technology to bio-sensing for the first time.

To accomplish this objective, we will first isolate circulating EVs using density-gradient ultracentrifugation from human OvCa patient plasma. We are currently collecting more than one hundred plasma samples per week from women suspected of OvCa malignancy through the UCDCC Biorepository resource. Second, we will be capturing EV subsets on our innovative sensors according to multiplexed capture agents like known general exosome-specific and also cancer-exosome-specific molecules, including the recently reported potent OvCa-binding peptide, LXY30. This enrichment method will provide unprecedented sensitivity towards TEX subpopulations. Third, we will use the nanomechanical resonance properties of hundreds of individual detectors, tuned to particular intrinsic EV-specific vibrating frequencies, to label-free sensitively detect small numbers of EVs. Fourth, we will apply custom nanomaterials composed of gold nanoparticles (NPs) and nanorods (NRs) coated with EV-targeting agents to further identify subpopulations of detector-captured EVs. We expect the detected signatures to be significantly more sensitive and specific than the current gold standard diagnostic approach, which may accelerate clinical cancer diagnostic platforms for a wide range of cancers.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Linking the Circadian Clock and Cancer**

*Host Campus:* Irvine

*Lead Investigator:* Selma Masri

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$75,000

*Abstract:*

The circadian clock controls several physiological, endocrine and metabolic processes that operate to maintain organismal homeostasis. These biological rhythms are self-perpetuating oscillations that are maintained within a 24-hour periodicity and are synchronized by external environmental cues such as light, temperature and food intake. Several lines of evidence undoubtedly suggest that disruptions in circadian rhythms results in numerous physiological disorders, including cancer. At the organismal level, genetic mutations in the circadian clock machinery accelerate tumorigenesis and this has been demonstrated in mouse models of leukemia/lymphoma, hepatocellular carcinoma, lung adenocarcinoma and osteosarcoma. At the molecular level, a crosstalk between the circadian clock and several oncogenic signaling pathways has been reported. Up-regulation of MYC has been shown to disrupt circadian gene expression and therefore perturb circadian glucose and glutamine metabolism in cancer cells. Conversely, the circadian clock has also been shown to target and degrade MYC, thereby inhibiting MYC-dependent proliferation. Additionally, the beta-catenin pathway has been reported to disrupt circadian gene expression, yet how clock disruption mechanistically drives enhanced beta-catenin signaling remains undetermined. We aim to further elucidate the molecular mechanisms related to the bi-directional crosstalk between the circadian machinery and cellular signaling pathways involved in survival and proliferation. Our work has the potential to open new avenues for therapeutic intervention targeting the circadian clock for the treatment of several cancers.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Downregulation of XIST in Ovarian Cancer and Its Mechanisms

*Host Campus:* Irvine

*Lead Investigator:* Sha Sun

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$75,000

*Abstract:*

This project aims to elucidate the functional role of cancer-associated long noncoding RNA (lncRNA), in particular, lncRNA XIST (X-inactive specific transcript) in ovarian cancer. Genome-wide association studies in cancer have revealed that more than 80% of cancer-associated genetic variations occur in noncoding sequences of the human genome. In parallel, an increasing number of cancer transcriptomes have also shown thousands of lncRNAs differentially expressed in a variety of human cancers when compared to normal cells. These indicate that understanding lncRNA-associated oncogenic pathways should be an important part of understanding the genetic mechanisms in cancer. The lncRNA XIST has recently been reported to affect cancer metastases and tumor progression. But whether the dysregulation of XIST can directly drive cancer symptoms, what are the XIST-mediated oncogenic pathways, and whether the lncRNA can be therapeutically targeted for cancer biomarkers are unclear. In addition, since XIST is known as the master regulator of X chromosome dosage compensation between XX female and XY male mammals, how XIST is regulated and whether differential expression of X-linked genes may affect female cancer in particular, are notable questions not fully addressed.

Research in my lab has focused on the positive and negative regulators of XIST and, for the first time, reported detailed molecular mechanisms for the function of another lncRNA, Jpx, in activating Xist in mice. To investigate possible mechanisms of XIST regulation in cancer, we have used the cBioPortal for cancer genomics and observed significant downregulation of XIST correlated with higher neoplasm histological grades of ovarian cancer. We hypothesize that XIST, with its activator JPX, can function as tumor suppressors influencing oncogenic pathways related to proliferation and metastasis. We propose to identify the tumor growth relevant pathways in which XIST and JPX are associated within ovarian cancer. We also aim to define the genetic mechanisms underlying the loss of XIST in tumor cells. The outcomes will contribute to the functional annotation of cancer-associated lncRNA and impact future development of RNA biomarkers that may inform cancer diagnosis and treatment.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Samoaan Healthy Eating and Active Living (HEAL)**

*Host Campus:* Irvine

*Lead Investigator:* Sora Tanjasiri

*Start Date:* 1/1/2020    *End Date:* 12/31/2020    *Amount:* \$74,910

*Abstract:*

Pacific Islanders (PIs) are disproportionately affected by the causes and contributing factors regarding cancer health disparities, as identified nearly 15 years ago by the U.S. Department of Health and Human Services (2004). Cancer is the leading cause of death for PIs, with obesity implicated as a causal factor in the onset of many cancers, including breast, colon, endometrium, esophagus, and kidney cancers. Unfortunately, relatively little is known about how to effectively prevent/reduce obesity among PIs who number 1.3 million in the U.S., 305,202 in California, and 88,050 in the San Francisco bay area. Responding to the National Cancer Institute's call for identifying factors influencing implementation of existing evidence-based interventions into community settings, we propose a multi-level, exploratory, implementation science pilot that applies the Consolidated Framework for Implementation Research (CFIR) to understand the factors associated with the potential adaptation to increase healthy eating and physical activity among Samoans in the bay area. The specific aims are to: 1) explore the organizational pre-implementation factors associated with program adoption among the parishes of the Samoaan Congregational Christian Church of American Samoa in the Northern California region. We will conduct key informant (KI) interviews with two leaders from each of 12 parishes (representing 3,000 Samoan members) to understand their perceptions of the barriers and facilitators to EBI adoption; and 2) identify the individual nutritional intake and physical activity levels among members from one parish. We will survey n=70 Samoan adults at this parish to estimate the point prevalence of current diet and physical activity behaviors to inform power analyses in the future R01. The research team is comprised of two academics and two community leaders, all of whom have worked together in the past and have expertise in Pacific Islander health and community-based participatory research. This exploratory study is the essential precursor to the design of a larger implementation study, and the results will inform the development of a larger implementation research proposal in response to the NIH PAR Dissemination and Implementation Research for Health or similar R01 opportunity.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Unveiling targets for treating malignancies of viral origin

*Host Campus:* Santa Barbara

*Lead Investigator:* Carolina Arias

*Start Date:* 1/1/2019    *End Date:* 12/31/2019    *Amount:* \$75,000

*Abstract:*

Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), two malignancies predominantly diagnosed in HIV/AIDS and immunocompromised patients. While the advent of antiretroviral therapy has significantly controlled the HIV/AIDS epidemic and has reduced the rates of AIDS-associated KS, infection with KSHV still prevails and causes serious disease in untreated HIV positive individuals and organ transplant patients. Treatment options for patients with severe KSHV-associated malignancies are limited, often involving exposure to chemotherapeutic agents with a wide range of secondary effects and cumulative toxicity. The development of new therapies for the control of KSHV infection in immunocompromised patients with mild to severe KSHV-related malignancies would expand the options for treatment of acute and chronic disease. An aspect of viral infection that remains to be explored for the development of antiviral agents is the strict dependence of viruses on their hosts. The pharmacological inhibition of cellular factors promoting infection or the activation of host pathways impairing viral replication has the potential to pave new avenues for the treatment of infections. This promising approach requires a deeper understanding of host/pathogen interactions at the molecular level. Here, we propose to identify critical cellular factors that are indispensable for KSHV infection, but dispensable for normal cell function, which could be targeted for therapeutic intervention. We will focus on understanding the regulation of viral protein synthesis in cells infected with KSHV. By dissecting the cellular requirements for the synthesis of functional proteins during viral infection, we will reveal potential host targets for the modulation of productive infection. Importantly, recent work showcases the clinical potential of pharmacological modulation of the protein synthesis and folding machinery for the treatment of cancer and other diseases. Our investigations will help pinpoint important host targets for the control of viral infections, offering the opportunity to explore drug repurposing to treat viral diseases, and providing an alternative for the management of KSHV-related malignancies in immunocompromised patients.



## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Studying tumor heterogeneity using single-cell epigenomics

*Host Campus:* Santa Barbara

*Lead Investigator:* Siddharth Dey

*Start Date:* 1/1/2019    *End Date:* 12/31/2019    *Amount:* \$75,000

*Abstract:*

While mutations and copy number variations in the genome are known drivers of cancer, there is increasing evidence that dysregulation in epigenetic marks such as DNA methylation (5-methylcytosine or 5mC) and disruption of the 3-dimensional organization of chromosomes within the nucleus of a cell play a critical role in the progression of tumors. In addition to these complex genome-wide transformations, tumors are also characterized by dramatic cellular heterogeneity that remain one of the major challenges in the effective treatment of cancer. However, it remains unclear how the epigenome influences tumor heterogeneity. This is because current measurements are typically made from a bulk population that fail to capture the cell-to-cell variability in 5mC or genome organization and the resulting gene expression heterogeneity. Further, while bulk studies in tumor cells have shown that large blocks of hypomethylation in 5mC appear to correlate with regions of the genome that interact with the nuclear periphery (known as lamina-associated domains or LAD), these experiments cannot distinguish if these profiles occur in the same cell or unrelated cells. Therefore, it remains unknown if a causal relationship exists between 5mC and genome organization, and how dynamic changes in such epigenetic features regulate cellular phenotypes. To overcome the technical challenges in addressing these questions and to understand how dysregulation in 5mC and genome organization together alter gene expression in tumor cells, we propose the following aims: (1) Develop a novel single-cell sequencing technology to simultaneously quantify 5mC, LAD organization and mRNA from the same cell. Integrated measurements of both the epigenetic features and the transcriptome will allow us to directly correlate 5mC to LAD structure and how they combine to regulate gene expression in a single cell. (2) Employ a recently developed model of tumor progression in intestinal organoids to study how simultaneous reprogramming of 5mC and LAD organization directly influences the dynamics of aberrant gene expression by the sequential introduction of mutations in APC, P53, KRAS and SMAD4 genes. This seed grant will lay the foundation for further systematic exploration into the potential mechanisms that mediate the cross-talk between 5mC and genome organization and its influence on gene regulatory networks.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Control of cell growth in normal and transformed cells**

*Host Campus:* Santa Cruz

*Lead Investigator:* Douglas Kellogg

*Start Date:* 1/1/2019    *End Date:* 12/31/2019    *Amount:* \$66,094

*Abstract:*

Cancer cells show severe defects in control of cell growth and size, yet the underlying causes are unknown. The long-term goal of our work is to discover how control of cell growth and size works in normal cells, and how it goes wrong in cancer cells. With this knowledge, we hope to identify novel vulnerabilities of cancer cells that can be exploited to improve therapies. Our work thus far has focused on budding yeast, since it provides a simple and powerful system in which to discover fundamental mechanisms of cell size control. In our recent work, we discovered that a highly conserved signaling network that surrounds TOR kinase complex 2 (TORC2) controls both cell growth and cell size. The network includes tumor suppressors, as well as numerous kinases directly involved in critical oncogenic signaling pathways. Our discovery that cell growth and size are controlled by a conserved signaling network that is known to be disrupted in cancer suggests that we are close to solving the mystery of why cancer cells show such severe defects in control of cell growth and size. We are now poised to translate our discoveries into vertebrate cells. We will test the hypothesis that key functions of the TORC2 network that we have discovered in yeast are conserved in vertebrates, and that they play important roles in oncogenic signaling. Successful completion of the Aims will provide fundamental new insights into the functions of important oncogenic signaling proteins, as well as insights into the poorly understood functions of the vertebrate TORC2 network.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Improving outcome of cancer chemotherapy with CO

Host Campus: Santa Cruz

Lead Investigator: Pradip Mascharak

Start Date: 1/1/2019    End Date: 12/31/2019    Amount: \$75,000

#### Abstract:

Recent studies have indicated that moderate doses (>250 ppm) of CO cause rapid reduction of some cancer cells (but not normal cell) through cell apoptosis. In addition, CO appears to sensitize cancer cells to chemotherapy. We have recently shown that that small doses of CO from designed CO-releasing molecules (photoCORMs) can be conveniently used to induce apoptosis in human breast cancer cells in a dose-dependent manner through controlled CO release. We now plan to determine whether such co-administration of exogenous CO increases the efficacy of chemotoxic drugs in the treatment of solid cancers (consequently minimizing treatment-related adverse events). We will utilize in-vitro and in-vivo models of breast and ovarian cancer for our investigation towards assessing the effects of exogenous CO applications. (1) We will determine the optimal concentrations of photoCORMs in diminishing cell proliferation of breast and ovarian cancer cells in-vitro and in xenograft models, in the presence of various doses of commonly used chemotoxic drugs, and (2) We will investigate the detailed mechanism(s) of CO-mediated inhibition of antioxidant pathways in breast and ovarian cancer cells in-vitro and in xenograft models. In both aims, use of photoCORMs will allow delivery of precise doses of CO and study its effects under very controlled conditions. In a recent paper [1], we have shown that CO delivery from our photoCORMs selectively inhibits cystathionine  $\beta$ -synthase (CBS, a heme protein) and attenuates the antioxidant capacity of human breast cancer cells. In cancer, CBS plays a significant role in drug resistance; silencing CBS expression could sensitize cancer cells to chemotherapeutics. Our results also demonstrated that exogenous CO delivery significantly increased the chemosensitivity of human breast cancer cells toward both Doxorubicin and Paclitaxel. We therefore plan to further explore the mechanism of CO-induced enhancement of chemotoxicity in both breast and ovarian cancer cells (especially cisplatin-resistant ovarian cancer cells). We believe that along with CBS, there could be other pathways also involved, for example metallothionein (MT) expression. This is a new venture in my research group and we plan to write a RO1 grant once we have more initial results to support our hypothesis. 1. J. Med. Chem. 2017, 60, 8000-8010.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Think Biology: Healthy Teen Lifestyles and Cancer Prevention**

*Host Campus:* Santa Barbara

*Lead Investigator:* Laura Romo

*Start Date:* 1/1/2019    *End Date:* 12/31/2019    *Amount:* \$66,941

*Abstract:*

Adolescence is an important life stage during which habits formed may shape trajectories of cancer risk later in life. Negative lifestyle behaviors such as smoking, drinking, use of other drugs, and risky sexual behavior start or peak during these years. Success in helping adolescents engage in self-protective health behaviors that reduces cancer risk depends on the availability of quality instructional materials. The overall goal of this study is to test the efficacy of a novel intervention program on high school adolescents' ability to attain and maintain healthy lifestyle behaviors that reduce cancer risk. We will create a program that utilizes theory-driven teaching practices in the field of science education. The Science of Learning approach posits that accumulated factual knowledge alone is insufficient to have a deep understanding of an area of inquiry. Science facts need to be understood in the context of a contextual framework organized around important core concepts to enable learners to construct explanations about bodily processes. Our curriculum will include a discussion of healthy lifestyles, bodily processes, the biology of cancer, and why certain health behaviors can increase the risk of cancer in adulthood. We will employ a group randomized-controlled-trial design to examine the effects of the newly developed curriculum against a control group of adolescents who are exposed to information about behaviors and cancer risk through standard pamphlets. Pamphlets tend to leave out information about the biology of cancer, bodily process, and their link to behaviors. Summative and formative assessments will be utilized to assess student learning. Misconceptions will be identified. Outcome measures will focus on knowledge gains, intentions, and engagements. The data gathered from this study will be utilized to apply for funding for a large-scale assessment program to develop materials that can be incorporated in high school biology courses. Current collaboration with medical professionals at Cottage Hospital. UCSB faculty collaborations: TBD

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Photothermal Therapy of Oral Squamous Cell Carcinoma**

*Host Campus:* Santa Cruz

*Lead Investigator:* Jin Zhang

*Start Date:* 1/1/2019    *End Date:* 12/31/2019    *Amount:* \$75,000

*Abstract:*

Actively targeted photothermal therapy (PTT) is a new and highly promising medical modality for cancer imaging and treatment. Oral cancer is the ninth most common cancer worldwide, and its prognosis remains poor in comparison to other cancer types, representing a continuing challenge in biomedicine. We propose to use a novel photothermal agent based on peptide-conjugated hollow gold nanospheres (P-HGNs) to actively target and treat oral squamous cell carcinoma (OSCC). The P-HGNs are designed with optimal size, shape, strong near infrared (NIR) light absorption, conjugation length, and high photothermal conversion efficiency. Instead of using antibody for targeting, we propose to use short peptides to reduce the distance between the HGNs and cancer cell or tissue to enhance heat transport and thereby PTT efficiency. Moreover, peptides, as recognition elements, are highly specific, yet inexpensive to produce, thus improving the translational potential of our constructs. We will conduct in vitro studies to validate the hypothesis that P-HGNs are highly effective for PTT applications, which lays the foundation for future in vivo studies.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Recurrent GLI mutations in drug-resistant skin cancer

*Host Campus:* Irvine

*Lead Investigator:* Scott Atwood

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

Basal cell carcinoma (BCC) are locally invasive skin cancers that affect over 4 million patients a year and are solely driven by activating mutations in the Hedgehog (HH) pathway. Inappropriate HH pathway activation also drives growth of a variety of cancers including brain, pancreatic, prostate, and small cell lung cancer that account for up to 25% of all human cancer deaths. The GLI1 and GLI2 transcription factors drive HH transcriptional output, with current therapies for advanced or metastatic BCCs limited to HH pathway antagonists that target proteins that lie upstream of the GLI transcription factors. Although effective, over 50% of advanced tumors display inherent drug resistance and 20% of tumors that do respond acquire drug resistance, indicating a critical need to understand the nature of drug resistance and to find the next generation of therapeutics. Towards this goal, we have found 110 mutations in GLI1 and GLI2 that may drive drug resistance by mining for recurrent mutations from our drug-resistant BCC patient tumor samples and cross referencing them to previously published tumor datasets across all sequenced cancers in the Catalogue of Somatic Mutations in Cancer (COSMIC) database. We have generated all 110 mutations and plan to stably express all variants in several HH responsive cell lines that include BCC lines ASZ001 and BSZ. We will characterize how each GLI mutation alters HH signaling, cell growth, and protein stability with a goal to identify specific clinically observed mutations that drive pathway activation. Positive hits that increase two out of the three criteria will be assayed for DNA binding, transcriptional activity, tumor growth, and drug resistance to understand how each mutation alters GLI function. So far, we have identified a cluster of mutations that disrupt interaction with the negative regulators PKA and SUFU, which significantly increases GLI activity levels. These results will provide insight on how GLI1 and GLI2 are regulated during HH pathway activation, how this regulation is altered during tumor growth and drug resistance, and will be invaluable in the discovery of future treatments for HH-dependent cancers.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Outcomes in Stage IV Cancer Patients with Bowel Obstruction

*Host Campus:* Davis

*Lead Investigator:* Robert Canter

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

Although patients and clinicians consider oncologic outcome and survival the pre-eminent goals of cancer therapy, quality of life (QOL) and avoidance of therapeutic morbidity, particularly among patients with stage IV cancer, are receiving increasing attention as important goals of care. Consequently, prolonged hospitalizations, intensive care stays, emergency room visits, hospital readmissions, and aggressive therapies, such as chemotherapy and surgery, have come under scrutiny given the increasing emphasis on improved palliative care and QOL for patients near their end of life. These issues create a dilemma for surgeons, as patients with disseminated malignancy (DMA) commonly present with acute surgical conditions, such as malignant bowel obstructions (MBO), for which surgery has historically been the standard of care. The goal of this proposal is to examine the morbidity, mortality and surrogate endpoints for QOL among patients with DMA who present with MBO and are treated medically versus surgically. We hypothesize that surgical management will lead to higher rates of these morbidity/adverse QOL outcomes with correspondingly negligible differences in overall survival. We will test our hypothesis through the following specific aims: Aim 1: To demonstrate that rates of morbidity and associated endpoints (e.g. prolonged hospitalizations) are higher for surgically-managed versus medically-managed DMA patients with MBO. Aim 2: To compare overall survival between the surgically and medically managed cohorts. We will test this hypothesis using the California Office of Statewide Health Planning and Development database, specifically consisting of patients with the diagnosis of DMA and MBO admitted to a California licensed hospital from 2005 to 2010. We will obtain inpatient and emergency visit data to evaluate differences in endpoints (i.e. morbidity, prolonged hospitalizations, ICU stays, readmission, emergency room visits and disposition to nursing facilities) for surgically versus medically-managed patients. In addition, we will use linked death data to examine differences in survival among cohorts. These data will have important implications for patients and surgeons as the data will provide a population-based assessment of the impact of medical versus surgical management on morbidity and survival as well as important metrics of QOL. This research is critical to shared patient and surgeon decision-making for this increasingly common and high risk patient population.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### R-loop Driven Oncogenic Translocations in Prostate Cancer

*Host Campus:* Davis

*Lead Investigator:* Frederic Chedin

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$53,424

*Abstract:*

Genomic instability is a hallmark of many cancers. This instability often results in oncogenic translocations such as the well-known MYC-IgH translocation in B cell tumors or TMPRSS2-ERG translocation in prostate cancers. Understanding the mechanisms driving such translocations is of critical importance for future therapies aimed at blocking these events. I hypothesize that co-transcriptional R-loop structures formed upon re-annealing of the nascent mRNA to the DNA template are a critical source of oncogenic translocations in prostate cancer. Building on groundbreaking genomics technologies developed by my laboratory, the first aim of this proposal will be to map sites of R-loop formation in prostate cells and their response to stimulation by androgen signaling. Pilot experiments show that R-loops significantly increase over androgen-responsive genes in response to androgen stimulation. Major common translocation partners such as TMPRSS2, NDGR1 and Kallikrein 3 (KLK3 – also known as prostate-specific antigen, PSA) show particularly strong increases in R-loop formation. The second aim of the proposal will test the hypothesis that co-transcriptional R-loops coincide with double-stranded DNA breaks that often initiate translocations. For this we will leverage the recently published END-seq method to map these breaks in prostate cells undergoing androgen stimulation or not. My group is well-versed in all the genomics techniques necessary for completing this work. We also have strong in-house expertise in computational biology including algorithm development and visualization techniques, necessary to analyze and cross-reference these large datasets. Overall, this proposal offers to leverage key breakthroughs in R-loop mapping developed by my group to the study of cancer initiation mechanisms. This represents a novel research direction for us. Upon completion of this 1-year grant, my goal is to extend this work into a more complete NIH R01 proposal aimed at characterizing mechanisms of genomic instability in prostate cancer.



## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Repurposing a toxin-immunity pair to selectively kill cancer

*Host Campus:* Irvine

*Lead Investigator:* Celia Goulding

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

One of the great remaining challenges in cancer therapy is the design of therapeutics that will selectively kill cancer cells, but leave healthy cells unharmed. A prevailing method of achieving selectivity comes from designing therapeutics that will bind to extracellular receptors; however, many of these markers are expressed in normal and germ cell tissues. Intracellular metabolic and gene expression profiles in cancer cells are instead drastically different from normal cells. It would therefore be transformative to develop targeted therapies that can 'sense' this intracellular difference, rather than a cell surface marker. Herein, we aim to develop such an approach; one that senses the intracellular environment of cancer cells, thereby triggering their destruction, by engineering a naturally occurring bacterial toxin-immunity complex to 'sense and kill' cancer cells and not normal healthy cells. We will fuse a known bacterial toxin, which is a potent DNase capable of completely degrading human chromosomal DNA, to its cognate toxin-neutralizing immunity protein. The toxin will be activated only by Cathepsin-L protease (CatL), a gene grossly upregulated in many cancer cells. Thus, the toxin will be liberated from the toxin-immunity fusion protein by CatL cleavage that will result in cancer cells death, whereas in healthy cells, which do not upregulate CatL, the toxin will remain fused to the immunity protein and therefore inactive. We will then test our optimized toxin-immunity fusion protein to ensure activation in human cancer cells and cell death, and that it remains inactivation in normal human cells. We shall also discuss potential delivery methods for this novel therapeutic; however experimental testing will out of the realm of this proposal. The final outcome of this design will be a state-of-the-art cancer-cell selective therapy. This initial CCRC study will generate data that will be used as proof-of-principle data for dual or multi-PI R01 NIH funding for anti-cancer therapeutics.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### The Role of p21 Phosphorylation at S123 in Tumor Suppression

Host Campus: Davis

Lead Investigator: Michael Kent

Start Date: 1/1/2018    End Date: 12/31/2018    Amount: \$55,000

#### Abstract:

The cyclin-dependent kinase (CDK) inhibitor p21, also known as WAF1 and CIP1, is a potent suppressor of cell growth and belongs to the Cip/Kip family of cdk inhibitors. p21 is a target of tumor suppressor p53 and mediates p53-dependent cell cycle arrest in response to DNA damage. Due to its potent role in growth suppression, p21 was originally identified as a tumor suppressor. Interestingly, recent studies also showed that p21 has an oncogenic activity as cytoplasmic localization of p21 promotes cell proliferation. Indeed, accumulation of cytoplasmic p21 is found in several types of cancers and associated with tumor progression and poor prognosis. Together, these studies suggest that depending on its cellular context, p21 could inhibit or promote tumorigenesis. Thus, understanding the mechanism how p21 activity is controlled may open a new avenue to explore p21 as a therapeutic target for cancer treatment. We previously cloned the canine CDKN1A gene and found that like human p21, canine p21 is induced by DNA damage in a p53-dependent manner and modulates p53-dependent cell cycle arrest. Interestingly, canine p21 is expressed as two isoforms due to proline-directed phosphorylation at serine 123 (S123), which can be easily visualized as a slower migrating band than the underphosphorylated canine p21. Interestingly, ectopic expression of mutant canine p21(S123D), in which serine 123 was substituted with phosphomimetic aspartate acid, greatly inhibited cell proliferation as compared to that of canine p21(S123A), in which serine 123 was replaced with non-phosphorylatable alanine. However, the role of serine 123 in p21-mediated growth suppression has not been studied in vivo. Interestingly, our pilot study indicated that the level of S123-phosphorylated p21 was reduced by lithium chloride (LiCl), an inhibitor of glycogen synthase kinase 3 (GSK3). Thus, we hypothesize that phosphorylation of serine 123 plays a critical role in p21-mediated growth suppression. To test this, we will determine: (1) whether GSK3 phosphorylates canine p21 at S123; (2) whether S123 phosphorylation enhances canine p21-mediated tumor suppression in vitro and in vivo.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Studying breast cancer initiation in single cell resolution

*Host Campus:* Irvine

*Lead Investigator:* Kai Kessenbrock

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

Breast cancer is one of the most prevalent forms of cancer in women worldwide. Despite recent advances in understanding the genetic mutations driving breast cancerogenesis, prognosis still remains poor especially due to late diagnosis and subsequent high mortality from metastatic tumor formation. One major scientific roadblock is that most of our scientific knowledge in cancer research is based on averaged ensemble analyses, although heterogeneity within the cell population is a striking feature of many tumors and plays a critical role in driving disease progression and therapy resistance. BRCA1+ carriers have a high risk of developing triple negative basal-type breast cancer, and thus commonly undergo prophylactic radical mastectomy. Studying these tissue samples from BRCA1+ carriers at pre-neoplastic and neoplastic stages offers a unique opportunity to study cancer initiation and progression in a primary human and clinically relevant setting. We hypothesize BRCA1-driven breast cancer leads to the disruption of the normal breast epithelial cell hierarchy and distinct systems-level changes in gene expression signatures not only within the subset of transformed tumor initiating cells, but also within other epithelial cell populations and non-epithelial microenvironmental components. We have established an interdisciplinary research approach utilizing comprehensive single cell RNAseq in combination with cutting edge bioinformatics pipelines to study tumor heterogeneity and to build a cell atlas delineating cancer initiation and progression in single cell resolution. By creating a cell atlas of the human breast in single cell resolution, and interrogating how the system goes awry during tumor initiation, we will identify disease promoting subpopulations, discover novel biomarkers and testable gene signatures to improve cancer early detection, and reveal novel therapeutic targets to prevent breast cancer from progressing into a life threatening condition. Ultimately, this project has the potential to revolutionize cancer genomics and precision medicine by introducing single cell genomics to translational breast cancer research, and thereby providing a first impetus towards the generation of a Single Cell Cancer Genome Atlas (SCCGA).

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Leukemia Stem Cells in B-Cell Acute Lymphoblastic Leukemia

*Host Campus:* Davis

*Lead Investigator:* Noriko Satake

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

Leukemia stem cells (LSCs) are the root of cancer and are responsible for treatment resistance and disease relapse. However, LSCs have not been identified in acute lymphoblastic leukemia (ALL), the most common cancer in children. Recently, our group discovered a method to identify and isolate LSCs from primary ALL samples. We demonstrated that the LSCs isolated using our marker have in vivo leukemia-initiating capability and distinct transcriptome profiles. We have identified 1,135 genes that are differentially expressed between LSCs and the counterpart of LSCs, non-LSCs ( $p < 0.05$ ). Of these, 315 genes are upregulated in LSCs. The goal of this project is to identify the gene(s) that regulate the “stemness” of LSCs in ALL. In this pilot study, we will focus on B-cell type ALL (B-ALL), the most common ALL in children. We will identify the genes which are important for LSC maintenance using an in vivo shRNA screening method and leukemia xenograft models with cell lines and primary leukemia samples. We hypothesize that one or more genes play a dominant role in regulating stemness and phenotypic properties of LSCs in B-ALL. The specific aims are to determine 1) the key genes associated with stemness in LSCs and 2) the key genes associated with differentiation in non-LSCs. We will investigate the two counterpart populations (LSCs and non-LSCs) using the same method, which should provide complementary results. We expect to identify potential novel genes (and pathways) which regulate the stemness of LSCs in B-ALL. We will pursue this goal using 1) our well-annotated series of patient-derived xenograft mouse models, 2) our novel LSC isolation technique, and 3) in vivo shRNA screening and targeted gene RNA sequencing. If successful, this project could have a significant impact on the most important challenges in cancer treatment: resistance or recurrence of disease.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Novel cancer metabolite-triggered drug delivery

*Host Campus:* Irvine

*Lead Investigator:* Szu-Wen Wang

*Start Date:* 1/1/2018    *End Date:* 12/31/2018    *Amount:* \$55,000

*Abstract:*

Stimuli-responsive drug delivery strategies are designed to react to changes in conditions, such as pH or temperature, within the microenvironment of tissues or cells. However, often these triggers are not adequately specific, as the conditions can occur at alternate off-target locations, or the differences between diseased vs. normal states are not sufficiently high. This proposed project will develop a novel drug delivery strategy that will target tumors by specifically responding to lactate, a signature metabolite of cancer and a hallmark of the Warburg effect. The Warburg effect has not yet been exploited in a drug release mechanism, so our proposed drug delivery material will introduce a novel means to deliver and release drug cargo to tumor environments with elevated lactate concentrations, and it is likely to be more specific towards cancer than existing approaches. We hypothesize that hydrogels responsive to the Warburg effect can be created by incorporating specifically-engineered lactate-binding proteins within polymeric matrices. The polymer component has been utilized in molecular imprinting, and the unique metabolite "sensor" will be engineered mutants of a protein with natural binding affinity to lactate. A small library of rationally-designed mutants will be created to obtain binding affinities appropriate for response. The protein and its polymerizable inhibitor will be incorporated into the hydrogel polymer, with interactions between the protein and inhibitor serving as reversible cross-linkers. Competitive binding of this material with the lactate in the microenvironment will result in material swelling and drug release. This proposed work will generate proof-of-concept data for future studies in metabolite-responsive drug therapy. Our aims are to: (1) engineer proteins that will competitively bind the lactate metabolite and its monomer inhibitor; (2) fabricate Warburg effect-responsive protein-polymer hydrogels; and (3) examine the hybrid materials' response to the lactate metabolite and the corresponding drug loading/release.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Investigating the carcinogenicity of e-cig**

*Host Institution:* University of Southern California

*Lead Investigator:* Stella Tommasi

*Start Date:* 7/1/2016      *Amount:* \$396,000

*Abstract:*

This project will address the overall health impact of electronic cigarette (e-cig) use, which is a major public health concern. E-cigs are increasingly promoted as safe alternatives to conventional tobacco cigarettes or as aids to smoking cessation. E-cigs are rapidly gaining acceptance in the United States and many parts of the world, especially among children and young adults. However, very little is known about the health consequences of e-cig use. The studies described in this "Pilot Research Award" application will investigate, for the first time, the cancer-causing potential of e-cig in a validated mouse model. We will use state-of-the-art DNA sequencing-based techniques, developed in our laboratory (Nucleic Acids Res, 2012) and others', to investigate the cancer-relevant biological effects of e-cig aerosol, and compare the results to those of cigarette smoke. Using a microprocessor-controlled vaping machine, we will expose mice to e-cig aerosol, harvest their lungs, and measure molecular changes that are known to be associated with cancer. The culmination of the studies described in this proposal is expected to result in data that can help clarify the health risks/benefits of e-cig use relative to cigarette smoking. This information will assist regulatory agencies in making scientifically based decisions on the development and evaluation of regulations on e-cigs and other tobacco products to protect public health and to reduce tobacco use by minors.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

# **Lung Cancer Screening: The Views of Patients and Physicians**

*Host Campus:* San Francisco

*Lead Investigator:* Celia Kaplan

*Start Date:* 7/1/2015     *Amount:* \$249,475

### *Abstract:*

Lung cancer is the leading cause of cancer death in the U.S. among both men and women. In 2010, results from the National Lung Screening Trial, which compared low-dose computed tomography (LDCT) screening to chest radiography, found a 20% reduction in lung cancer mortality among individuals at high risk who received LDCT. Based on these results, and after evaluating the benefits and harms, the United States Preventive Services Task Force recommended annual lung cancer screening with LDCT scans for high-risk patients. Recently, the Centers for Medicare and Medicaid Services announced the decision to cover LDCT for lung cancer screening. Considering these recommendations, patients, together with their physicians, should weigh currently known benefits with limitations and risks to make an informed and shared decision about being screened.

Any discussion of lung cancer screening should be coupled with culturally and linguistically personalized information about risk and potential benefits, harms, limitations, and associated costs. Although primary care physicians (PCPs) are central to the discussion of lung cancer screening and shared decision making, they may lack tools and information to facilitate these discussions with patients. In addition, patients lack the personalized information to determine their own risk and to evaluate the benefits and harms of lung cancer screening. However, there are no standards for conducting these discussions, particularly with patients of limited health literacy, limited English proficiency or from diverse cultural backgrounds.

Our study will assess the barriers and facilitators of lung cancer screening among a multiethnic population and determine the best methods and messages for communicating risk, benefits, and options for lung cancer screening. We will determine the barriers (psychosocial, financial, system) to physician-patient discussions concerning lung cancer risk and lung cancer screening, and determine what might facilitate those discussions and encourage SDM. We will evaluate patient and PCP perspectives and concerns individually.

We expect our research to provide specific recommendations that will inform an intervention to facilitate patient-PCP discussions about LDCT screening and promote shared decision-making among ethnically diverse patients.

## Cancer Research Coordinating Committee

Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions

### Genomic approaches to identify SCLC biomarkers

*Host Institution:* Stanford University

*Lead Investigator:* Dian Yang

*Start Date:* 7/1/2015      *Amount:* \$63,364

*Abstract:*

Small cell lung cancer(SCLC) is the most deadly type of lung cancer and is associated with heavy cigarette smoking. Although the five-year survival rate is only 15%, the few patients detected with limited-stage disease have a much higher long-term survival. Therefore, it is crucial to identify targets and develop methods that could detect SCLC with high specificity in high-risk patients at early stages of cancer development.

We hypothesized that genes/markers that uniquely label SCLC in the lung would be good candidate for cancer detection. Our preliminary gene expression analysis comparing differences between SCLC lung tumors and normal lung tissue suggests that SCLC tumors have very distinct gene expression profiles with more than a thousand of genes changed their expression level for more than four fold. The defined timeline of tumor development in genetically engineered mouse models of SCLC enables us also to look into even early stage lesions, called hyperplasia. By cross comparison the gene expression patterns among normal lung cells, hyperplasia and SCLC tumors, we will gain a full understanding of early cancer development, but also identify a list of candidate markers for both hyperplasia and tumors. We will query other mouse model of SCLC as well as publicly available human SCLC gene expression dataset to filter our candidate marker list and finalize a list of markers that are generalizable and universal to most SCLC cases. We anticipate getting a list of 10 candidates for further characterization. We will then validate the candidates' expression at protein level using immunohistochemistry on SCLC tumor sections from mouse and human. Given the imperative need for better therapies for SCLC, we will also test whether the candidate markers of SCLC have functional importance during tumor development. We will decrease the candidates' expression by RNAi technology, and monitor the effect on tumor growth in mouse and also effects on proliferation and cell death.

An understanding of the markers that uniquely label SCLC in the lung may allow the clinical development of imaging methods that detect SCLC with high sensitivity and specificity. Functionally important candidates may also be potential drug targets for treating SCLC.



## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **CTCs for early detection and characterization of lung cancer**

*Host Institution:* SRI International

*Lead Investigator:* Xiaohe Liu

*Start Date:* 12/1/2014    *Amount:* \$351,236

*Abstract:*

Circulating tumor cells (CTCs) are cells that are released from primary tumors into the bloodstream, thereby contributing to the spread of cancer to other parts of the body. They circulate in very low concentration in the peripheral blood and are not readily detected with conventional technologies. The Holy Grail of cancer diagnostics is the “liquid biopsy”: the ability to use the CTC information available in a blood specimen to diagnose and characterize cancer.

We have developed an innovative technology for rare cell detection called FAST (Fiber-optic Array Scanning Technology) that detects CTCs with high sensitivity and speed. For many years, our laboratory has investigated better ways to detect cancer and personalize and monitor treatments by identifying and characterizing CTCs from multiple cancer types, such as breast, lung and prostate cancers. Our characterization of CTCs analyzes protein biomarkers and genetic traits to provide information about the specific nature of a given patient’s disease and identify potential effective therapies.

The large majority (85–90%) of lung cancers are non-small cell lung cancer (NSCLC), and this aggressive disease has low survival rates. Producing an effective liquid biopsy technique could increase survival and potentially eliminate traditional biopsies, which are not only expensive but are invasive in ways that take an emotional and physical toll on patients.

Our goal is to develop new methods that can accurately detect CTCs from NSCLC with high sensitivity, thereby identifying cancer at a much earlier stage, when treatment can be much more successful. In addition, we propose to develop novel multiplexed assays to characterize molecular targets on CTCs at the single-cell level. These biomarkers will provide extensive, real-time information to allow treatment to be tailored to a patient’s specific cancer. This study is designed to generate data that can be used to pave the way for personalized medicine and better outcomes for NSCLC patients.

## Cancer Research Coordinating Committee

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### Ultra Low Dose, Effective CT for Lung Cancer Screening

*Host Campus:* Los Angeles

*Lead Investigator:* Michael McNitt-Gray

*Start Date:* 8/1/2013      *Amount:* \$428,183

#### *Abstract:*

Lung cancer is the leading cause of cancer death in both men and women in the United States. The disease has been closely associated with smoking since 1964, when the Surgeon General concluded that tobacco smoke was a cause of lung cancer. Today, smoking is thought to cause up to 80-90 percent of lung cancer cases. Many programs have been successful in limiting smoking (e.g. smoking cessation programs, laws and policies that limit exposure to second hand smoke, etc.). However, lung cancer 5 year survival rates have not improved dramatically in the past several decades. The five-year survival rate for lung cancer currently stands at 15.6 percent as compared to an over 90 percent survival rate for breast, colon and prostate cancers.

In October 2010, the National Lung Screening Trial (NLST) announced it had demonstrated a significant reduction in death rates from lung cancer (and death from any cause) when performing screening using low dose CT. More than 2 years later and despite the success of this trial and the endorsement of many agencies recommending the use of CT in screening in high risk populations (The American Cancer Society, The American Lung Association, The American College of Chest Physicians, the American Society of Clinical Oncology, The American Association for Thoracic Surgery and the National Comprehensive Cancer Network), there has not been widespread adoption of CT screening for lung cancer.

While several reasons for this lack of adoption have been identified, one recurrent reason given is the concern over radiation exposure to a large screening population, even with low dose CT. The scans performed in the NLST were considered to be "low dose" because they used an appreciably reduced scanner output (compared to conventional diagnostic CT scans) to carry out these screening studies. Since the NLST was initiated in 2002, there have been tremendous advances in CT scanner technology, specifically with respect to radiation dose reduction. These include the introduction of automatic exposure controls which adapt the scanner output to the size of the patient (reducing it for small patients, etc.) and novel image reconstruction methods that exploit advances in computing power to reduce image noise and allow image quality to be maintained even when very low doses are used. These developments encourage us that lung cancer screening may be accomplished using CT at doses that are significantly lower than the "low dose" scans used in the NLST.

Therefore, there is a critical need to develop Ultra Low Dose CT scanning methods that bring the radiation dose down to a level close to that of Chest X-rays while maintaining the image quality necessary for lung cancer screening. The purpose of this project is to investigate both methods to perform CT exams at reduced dose levels close to those of Chest X-rays and to evaluate the ability to identify and characterize lung nodules in a screening setting under these ultra low dose scanning conditions. This requires an innovative approach which brings together imaging physics, image reconstruction methods and computer vision techniques with specific emphasis on detection of lung lesions and their boundaries.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Shared Genetics of COPD and Lung Cancer**

*Host Institution:* Kaiser Foundation Research Institute, a Division of Kaiser Foundation Hospitals

*Lead Investigator:* Lori Sakoda

*Start Date:* 8/1/2013      *Amount:* \$561,107

*Abstract:*

Why some smokers develop lung cancer, but most do not, remains unclear. Answering this question is critical in improving prevention and early detection of this deadly disease. People with chronic obstructive pulmonary disease (COPD) have a much greater risk of developing lung cancer. Since smoking is the major cause of both COPD and lung cancer, these diseases likely arise from some common biological mechanisms that are activated by tobacco smoke. These mechanisms may be discovered by determining whether genetic characteristics associated with risk for developing COPD are also associated with risk for developing lung cancer. The primary goal of our study is to identify genetic characteristics that jointly contribute to COPD and lung cancer in smokers.

To achieve this, we will identify former and current smokers diagnosed with COPD, with lung cancer, or without either condition as participants from a large, stable, and well-characterized cohort of adult Kaiser Permanente Northern California health plan members. For all participants, survey data on lifestyle and behavioral characteristics, along with extensive genetic data, have already been collected. Genetic data include genome-wide single nucleotide polymorphism (SNP) genotyping and telomere length measures. In analyzing these data, we will first identify genetic characteristics associated with risk of COPD. We will then assess the extent to which COPD-related SNPs identified in this and prior studies and telomere length are associated with risk of (a) both COPD and lung cancer, (b) lung cancer with pre-existing COPD, and (c) lung cancer without pre-existing COPD.

The proposed study will be the most comprehensive examination of shared genetic risk factors for COPD and lung cancer to date. Identifying genetic characteristics associated with COPD and/or lung cancer has the potential to not only improve our understanding of the biological mechanisms involved in both tobacco-related diseases, but also lead to the discovery of new chemopreventive and therapeutic drugs and the development of tailored early detection strategies for lung cancer.

## **Cancer Research Coordinating Committee**

*Abstracts for Awards Supported Through California Cancer Research Voluntary Tax Contributions*

### **Alliance for Data Dissemination to Achieve Equity (ADEPT)**

*Host Institution:* Asian Pacific Partners for Empowerment, Advocacy and Leadership (APPEAL)

*Lead Investigator:* Rod Lew

*Start Date:* 5/1/2011      *Amount:* \$481,501

*Abstract:*

This proposed collaborative project, Alliance for Data dissemination to achieve Equity for Priority populations on Tobacco (ADEPT), will contribute to TRDRP's mission and goals, by helping to understand and translate tobacco use information from California's diverse population through the dissemination and evaluation of high quality, evidence-based data. It will address TRDRP's primary area of tobacco-related health disparities among California's diverse and vulnerable populations including African Americans (AfAms), American Indian/Alaskan Natives (AIs/ANs), Asian Americans (AAs), Native Hawaiians and Pacific Islanders (NHPIs), Hispanic/Latinos (H/Ls), Lesbian, Gay, Bisexual, Transgender (LGBT) and low Socioeconomic Status (low SES) populations. ADEPT will disseminate critical tobacco use data on these 7 diverse and vulnerable populations in culturally and language specific community-tailored format. This will help to increase the understanding of the impact of tobacco use on vulnerable populations and lead to increased mobilization on tobacco control program and policy initiatives. Furthermore, in addition to an individual community-tailoring approach to data dissemination, ADEPT will facilitate a collaborative approach to planning, sharing common strategies and joint event(s) among all 6 priority population groups.